<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006313.pub3" GROUP_ID="ANAESTH" ID="707106012617300799" MERGED_FROM="" MODIFIED="2017-02-14 17:09:36 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="042" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2017-02-14 17:09:35 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE>Intravenous versus inhalation anaesthesia for one-lung ventilation</TITLE>
<CONTACT MODIFIED="2017-02-14 17:09:35 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="9DA0FCBF82E26AA2007D5B6E4992F15C" ROLE="AUTHOR"><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>El Dib</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>eldib@fmb.unesp.br</EMAIL_1><EMAIL_2>re.lucci@terra.com.br</EMAIL_2><MOBILE_PHONE>+55 11 9999 6647</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Biosciences and Oral Diagnosis</DEPARTMENT><ORGANISATION>Institute of Science and Technology, Unesp - Univ Estadual Paulista</ORGANISATION><CITY>Botucatu</CITY><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-02-14 17:09:35 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="64422251167871786596110726124914" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Norma</FIRST_NAME><MIDDLE_INITIALS>SP</MIDDLE_INITIALS><LAST_NAME>Módolo</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>nmodolo@fmb.unesp.br</EMAIL_1><MOBILE_PHONE>+ 55 14 9743 0211</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 3811 6222</PHONE_1><FAX_1>+55 14 3811 6222</FAX_1></ADDRESS></PERSON><PERSON ID="62986732832750009020110726125304" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Marília</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Módolo</LAST_NAME><POSITION>Medical graduation student</POSITION><EMAIL_1>mapmodolo@gmail.com</EMAIL_1><EMAIL_2>gotacola@hotmail.com</EMAIL_2><MOBILE_PHONE>+ 55 14 9743 0211</MOBILE_PHONE><ADDRESS><ORGANISATION>Botucatu Medical School, UNESP - Univ Estadual Paulista</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu</CITY><ZIP>18603-970</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 3811 6222</PHONE_1><FAX_1>+55 14 3811 6222</FAX_1></ADDRESS></PERSON><PERSON ID="41992449110938012428110726125638" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Marcos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Marton</LAST_NAME><POSITION>Medical graduation student</POSITION><EMAIL_1>marcos_marton@yahoo.com.br</EMAIL_1><EMAIL_2>marcos_marton@hotmail.com</EMAIL_2><MOBILE_PHONE>+ 55 14 9765 2416</MOBILE_PHONE><ADDRESS><ORGANISATION>Botucatu Medical School, UNESP - Univ Estadual Paulista</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu</CITY><ZIP>18603-970</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 3811 6070</PHONE_1><FAX_1>+55 14 3811 6222</FAX_1></ADDRESS></PERSON><PERSON ID="73698791577924593147120529104741" ROLE="AUTHOR"><FIRST_NAME>Enilze</FIRST_NAME><LAST_NAME>Volpato</LAST_NAME><POSITION>Librarian</POSITION><EMAIL_1>enilze@btu.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Library</DEPARTMENT><ORGANISATION>Universidade Estadual Paulista Júlio de Mesquita Filho/ UNESP</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior s/n</ADDRESS_1><CITY>Botucatu</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 14 3811 6222</PHONE_1></ADDRESS></PERSON><PERSON ID="z1301241146001904145495004920137" ROLE="AUTHOR"><FIRST_NAME>Vinícius</FIRST_NAME><LAST_NAME>Monteiro Arantes</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>viniciusma43@yahoo.com.br</EMAIL_1><EMAIL_2>viniciusmonteiroarantes@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, UNESP - Univ Estadual Paulista</ORGANISATION><ADDRESS_1>Rua Ranimiro Lotufo, 545 - casa 3</ADDRESS_1><CITY>Botucatu</CITY><ZIP>18606770</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="z1211151020271031194113164573258" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paulo</FIRST_NAME><LAST_NAME>do Nascimento Junior</LAST_NAME><EMAIL_1>pnasc@fmb.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesiology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>Distrito de Rubião Júnior, s/n</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><ZIP>18603-970</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 14 3811 6222</PHONE_1><FAX_1>+ 55 14 9778 3075</FAX_1></ADDRESS></PERSON><PERSON ID="9DA0FCBF82E26AA2007D5B6E4992F15C" ROLE="AUTHOR"><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>El Dib</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>eldib@fmb.unesp.br</EMAIL_1><EMAIL_2>re.lucci@terra.com.br</EMAIL_2><MOBILE_PHONE>+55 11 9999 6647</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Biosciences and Oral Diagnosis</DEPARTMENT><ORGANISATION>Institute of Science and Technology, Unesp - Univ Estadual Paulista</ORGANISATION><CITY>Botucatu</CITY><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-02-13 18:27:49 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="7" MONTH="2" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="2" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="9" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2017-02-14 11:38:06 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-02-14 11:37:46 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="14" MONTH="2" YEAR="2017"/>
<DESCRIPTION>
<P>
<BR/>New search run to February 2017, four new studies not fully incorporated and awaiting classification</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-02-14 11:38:06 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-02-14 11:38:06 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="12" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-12 12:31:41 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="4" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>In the previous version (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>), the databases were searched until 2006. We reran the searches until November 2012. We have included risk of bias, summary of finding tables and a new study flow diagram.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-11-12 12:31:44 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="4" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>This review is an update of the previous Cochrane systematic review (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>) that included nine RCTs (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>) and enrolled 291 participants.</P>
<P>The previous authors Adriana Bassi, Wilson RO Milani and Delcio Matos decided not to update the review (new authors: Norma SP Módolo, Marília P Módolo, Marcos A Marton, Enilze Volpato, Vinícius M Arantes and Regina P El Dib have updated this version).</P>
<P>We found 11 new trials (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>) that met our inclusion criteria.</P>
<P>In general, our review reaches the same conclusions as the original review (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>). However, we included more trials, and thus have the opportunity to plot the new trials on the following outcomes: intraoperative awareness and adverse postoperative outcomes.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-29 10:58:47 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="2" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to the new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-05-26 20:08:15 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-05-26 20:08:15 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-05-26 20:08:15 +0100" MODIFIED_BY="[Empty name]">
<NAME>Own support</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-02-14 11:49:59 +0000" MODIFIED_BY="Jane Cracknell">
<SUMMARY MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2012-04-10 16:25:38 +0100" MODIFIED_BY="[Empty name]">Intravenous versus inhalation anaesthesia for one-lung ventilation</TITLE>
<SUMMARY_BODY MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Clinicians may choose to ventilate only one of a patient's two lungs either during surgery or during a period of intensive care. Possible reasons are to facilitate the performance of surgery, to prevent lung rupture, and to prevent contamination of one lung by the other. During one-lung ventilation, anaesthesia is maintained by delivery of an inhalation anaesthetic, such as sevoflurane, to the ventilated lung, or by infusion of an intravenous anaesthetic, for example, propofol. It is possible that the method chosen to maintain anaesthesia may affect patient outcomes. We included 20 studies that enrolled 850 participants in this updated systematic review. The methodological quality of the included studies was uncertain because of poor reporting. No evidence indicated that the drug used to maintain anaesthesia during one-lung ventilation affected patient outcomes. Researchers should include outcomes that are important to participants when assessing the effects of anaesthetic technique during one-lung ventilation. These include adverse postoperative effects, death and intraoperative awareness. </P>
<P>We reran the search in February 2017 and found four potential studies of interest which have been added to a list of 'Studies awaiting Classification' and will be incorporated into the formal review findings during the review update.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-02-14 11:49:50 +0000" MODIFIED_BY="Jane Cracknell">
<ABS_BACKGROUND MODIFIED="2013-07-01 14:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in <I>The Cochrane Library,</I> Issue 2, 2008.</P>
<P>The technique called <I>one-lung ventilation</I> can confine bleeding or infection to one lung, prevent rupture of a lung cyst or, more commonly, facilitate surgical exposure of the unventilated lung. During one-lung ventilation, anaesthesia is maintained either by delivering an inhalation anaesthetic to the ventilated lung or by infusing an intravenous anaesthetic. It is possible that the method chosen to maintain anaesthesia may affect patient outcomes. Inhalation anaesthetics may impair hypoxic pulmonary vasoconstriction (HPV) and increase intrapulmonary shunt and hypoxaemia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-06-11 02:45:01 +0100" MODIFIED_BY="Jane Cracknell">
<P>The objective of this review was to evaluate the effectiveness and safety of intravenous versus inhalation anaesthesia for one-lung ventilation.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-02-14 11:49:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL); <I>The Cochrane Library</I> (2012, Issue 11); MEDLINE (1966 to November 2012); Embase (1980 to November 2012); Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS, 1982 to November 2012) and ISI web of Science (1945 to November 2012), reference lists of identified trials and bibliographies of published reviews. We also contacted researchers in the field. No language restrictions were applied. The date of the most recent search was 19 November 2012. The original search was performed in June 2006.</P>
<P>We reran the search in CENTRAL, MEDLINE, Embase, LILACS, and ISI web of Science in February 2017 and found four potential studies of interest which have been added to a list of 'Studies awaiting Classification' and will be incorporated into the formal review findings during the review update.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-07-01 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials and quasi-randomized controlled trials of intravenous (e.g. propofol) versus inhalation (e.g. isoflurane, sevoflurane, desflurane) anaesthesia for one-lung ventilation in both surgical and intensive care participants. We excluded studies of participants who had only one lung (i.e. pneumonectomy or congenital absence of one lung).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-01 14:40:05 +0100" MODIFIED_BY="Dolores Matthews">
<P>Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-07-01 14:40:15 +0100" MODIFIED_BY="[Empty name]">
<P>We included in this updated review 20 studies that enrolled 850 participants, all of which assessed surgical participants&#65293;no studies investigated one-lung ventilation performed outside the operating theatre. No evidence indicated that the drug used to maintain anaesthesia during one-lung ventilation affected participant outcomes. The methodological quality of the included studies was difficult to assess as it was reported poorly, so the predominant classification of bias was 'unclear'.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-07-01 14:40:42 +0100" MODIFIED_BY="[Empty name]">
<P>Very little evidence from randomized controlled trials suggests differences in participant outcomes with anaesthesia maintained by intravenous versus inhalational anaesthesia during one-lung ventilation. If researchers believe that the type of drug used to maintain anaesthesia during one-lung ventilation is important, they should design randomized controlled trials with appropriate participant outcomes, rather than report temporary fluctuations in physiological variables.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-02-14 11:49:59 +0000" MODIFIED_BY="Jane Cracknell">
<BACKGROUND MODIFIED="2013-07-01 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-07-01 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in <I>The Cochrane Library, </I>Issue 2, 2008 (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>). The original review included nine studies (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>), and no evidence from randomized controlled trials showed differences in patient outcomes with anaesthesia maintained by intravenous versus inhalational anaesthesia during one-lung ventilation.</P>
<P>Clinicians may choose to ventilate only one of a patient's two lungs during surgery or during a period of intensive care. This technique, called <I>one-lung ventilation</I> (OLV), can confine bleeding or infection to one lung, prevent rupture of a lung cyst or, more commonly, facilitate surgical exposure of the unventilated lung (<LINK REF="REF-Morgan-2001" TYPE="REFERENCE">Morgan 2001</LINK>). During OLV, anaesthesia is maintained by delivery of an inhalation anaesthetic to the ventilated lung or by infusion of an intravenous anaesthetic. It is possible that the method chosen to maintain anaesthesia can affect patient outcomes by modifying the physiological changes that occur during OLV.</P>
<P>Blood that flows through the unventilated lung cannot be oxygenated and, therefore, contributes to arterial hypoxaemia. Blood flow through the unventilated lung can be reduced by factors acting outside the lung tissue or by factors acting inside the lung. In addition, impedance of blood flow through the ventilated lung will indirectly affect blood supply to the unventilated lung. Blood supply to the unventilated lung may be reduced by mechanical compression and distortion of the pulmonary vessels, by reduced pulmonary arterial pressure or by reduced right ventricular stroke volume. Blood flow within lung tissue may be reduced by mechanical distortion or by constriction of smaller pulmonary vessels. Pulmonary arterioles contract when the oxygen tension is low, and inhalation anaesthetics and intravenous anaesthetics may affect this 'hypoxic pulmonary vasoconstriction' differently (<LINK REF="REF-Friedlander-1994" TYPE="REFERENCE">Friedlander 1994</LINK>).</P>
<P>Clinically applicable measures used to maintain oxygenation during OLV include high oxygen concentration of inspired air, intermittent inflation or continuous positive airway pressure to the unventilated lung and positive end-expiratory pressure to the ventilated lung (<LINK REF="STD-Saito-2000" TYPE="STUDY">Saito 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-06-26 03:00:59 +0100" MODIFIED_BY="[Empty name]">
<P>The inhalation anaesthetics seem to impair hypoxic pulmonary vasoconstriction (HPV) more than intravenous anaesthetics by increasing intrapulmonary shunt and hypoxaemia (<LINK REF="REF-Domino-1986" TYPE="REFERENCE">Domino 1986</LINK>; <LINK REF="REF-Loer-1995" TYPE="REFERENCE">Loer 1995</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>), although this effect might be mediated by an alveolar inflammatory response (<LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-07-01 14:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>The level of oxygenation during one-lung ventilation may be altered by the type of anaesthesia agent used. Abolition of hypoxic pulmonary vasoconstriction by anaesthetic agents has been suggested as a cause of hypoxaemia during anaesthesia. Early studies demonstrated that inhalation anaesthetics inhibited this vasoconstriction whilst injectable agents did not (<LINK REF="REF-Marshall-1984" TYPE="REFERENCE">Marshall 1984</LINK>).</P>
<P>Studies have compared different types of inhalation agents and inhalation anaesthesia with intravenous agents (<LINK REF="STD-Abe-1998a" TYPE="STUDY">Abe 1998a</LINK>; <LINK REF="STD-Benumof-1987" TYPE="STUDY">Benumof 1987</LINK>; <LINK REF="STD-Carlsson-1987" TYPE="STUDY">Carlsson 1987</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>). No systematic review has summarized the results of these trials.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-07-01 14:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Currently there is no straightforward recommendation based on systematic reviews of previous trials of the effects of anaesthetic agents for one-lung ventilation. The rate of death or morbidity might be particularly high after OLV, so any intervention that reduces this risk would be useful (<LINK REF="REF-Harpole-1999" TYPE="REFERENCE">Harpole 1999</LINK>; <LINK REF="REF-Wada-1998" TYPE="REFERENCE">Wada 1998</LINK>). </P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-07-01 14:46:43 +0100" MODIFIED_BY="John B Carlisle">
<P>The objective of this review was to evaluate the effectiveness and safety of intravenous versus inhalation anaesthesia for one-lung ventilation.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-02-14 11:49:59 +0000" MODIFIED_BY="Jane Cracknell">
<SELECTION_CRITERIA MODIFIED="2013-07-01 14:50:11 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-06-03 12:12:24 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomized and quasi-randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-07-01 14:49:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>We included participants ventilated by one lung.</LI>
<LI>We included both surgical and intensive care participants.</LI>
<LI>We excluded participants who had only one lung (i.e. pneumonectomy or congenital absence of one lung).</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-07-01 14:49:59 +0100" MODIFIED_BY="[Empty name]">
<P>Maintenance of anaesthesia during one-lung ventilation with inhalation anaesthesia (e.g. isoflurane, sevoflurane, desflurane) versus total intravenous anaesthesia (e.g. propofol).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-07-01 14:50:11 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-07-01 14:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>We measured the following primary outcomes:</P>
<UL>
<LI>Mortality rate (during the total observation period);</LI>
<LI>Adverse postoperative outcomes, such as brain damage, heart failure, myocardial infarction and blood transfusion (analysed separately); and</LI>
<LI>Intraoperative awareness (as subsequently reported by the participant).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-01 14:50:08 +0100" MODIFIED_BY="[Empty name]">
<P>Our secondary outcomes were:</P>
<UL>
<LI>death at one month and six months;</LI>
<LI>abandonment of one-lung technique;</LI>
<LI>length of stay in hospital; and</LI>
<LI>economic analysis (by narrative).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-02-14 11:49:59 +0000" MODIFIED_BY="Jane Cracknell">
<P>We conducted systematic searches for randomized controlled trials. No language, publication year or publication status restrictions were applied. The date of the last search was February 2012.</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-02-14 11:49:59 +0000" MODIFIED_BY="Jane Cracknell">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL); <I>The Cochrane Library</I> (2012, Issue 11); MEDLINE (1966 to November 2012); Embase (1980 to November 2012); Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS, 1982 to November 2012) and ISI Web of Science (1945 to November 2012).</P>
<P>We reran the search in CENTRAL, MEDLINE, Embase, LILACS, and ISI web of Science on February 7, 2017 and found four potential studies of interest which have been added to a list of 'Studies Awaiting Classification' and will be incorporated into the formal review findings during the review update.</P>
<P>Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for our bibliographic search strategies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-07-01 14:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of identified relevant studies for additional citations; contacted specialists in the field and authors of the included trials for unpublished data and contacted pharmaceutical manufacturers to verify the data and obtain additional unpublished data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-07-01 14:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (NSPM and RPED) independently screened trials identified by the literature search, extracted the data, assessed trial quality and analysed the results. If consensus was not reached, we did not include the data from the trials in question unless and until the authors of those trials were able to resolve the contentious issues.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-07-01 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (NSPM and RPED) independently extracted data. We resolved any discrepancies by discussion. We used a standard form (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) to extract the following information: characteristics of the study (design, methods of randomization); participants; interventions and outcomes (types of outcome measures, timing of outcomes, adverse events). Our data extraction form was based on recommendations made by the Cochrane Anaesthesia Review Group.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-07-01 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>We used the new risk of bias approach for Cochrane Reviews to assess study quality (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Two review authors (NSPM and RPED) independently assessed the following six separate criteria. We resolved any discrepancies by discussion:</P>
<UL>
<LI>Adequate sequence generation;</LI>
<LI>Allocation concealment;</LI>
<LI>Blinding;</LI>
<LI>Incomplete outcome data;</LI>
<LI>Selective outcome reporting; and</LI>
<LI>Other sources of bias.</LI>
</UL>
<P>In the first step, we copied information relevant for making a judgement on a criterion from the original publication into an assessment table. If additional information was available from study authors, we entered this in the table along with an indication that this was unpublished information. Two review authors (NSPM and RPED) independently made a judgment as to whether the risk of bias for each criterion was considered to be 'low', 'uncertain' or 'high'. We resolved disagreements by discussion. We considered that trials categorized as 'low risk' for all six criteria were low bias-risk trials. </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-07-01 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Binary outcomes</HEADING>
<P>For dichotomous data, we used the risk ratio (RR) as the effect measure with 95% confidence intervals (CIs).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continuous outcomes</HEADING>
<P>For continuous data, we presented the results as mean differences (MDs) with 95% CIs. When pooling data across studies, we estimated the MD if the outcomes were measured in the same way. We used the standardized mean difference (SMD) to combine trials that used different methods to measure the same outcome.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-07-01 14:52:13 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was one outcome for each participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-07-01 14:52:25 +0100" MODIFIED_BY="[Empty name]">
<P>We assumed that participants who dropped out were nonresponders.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-01 14:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>We intended to quantify inconsistency among the pooled estimates using the I<SUP>2</SUP> statistic. This illustrates the percentage of variability in effect estimates that results from heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We also intended to examine forest plots for CI overlap and to calculate the Chi<SUP>2</SUP> test for homogeneity with a 10% level of significance. We used I<SUP>2</SUP> statistical values to categorize heterogeneity: less than 25%; 25% to 50%; 50% to 75% and greater than 75%.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-07-01 14:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>Apart from assessing the risk of selective outcome reporting considered under assessment of risk of bias in included studies, we intended to assess the effects of small studies by using funnel plots, when at least 10 trials were identified. 
</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-07-01 14:52:51 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use the fixed-effect model to analyse data. If I<SUP>2</SUP> was greater than 50%, we intended to use random-effects models. We planned to undertake quantitative analyses of outcomes on an intention-to-treat basis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-01 14:53:14 +0100" MODIFIED_BY="[Empty name]">
<P>We planned the following subgroup analyses: different intravenous anaesthetics; different dosages of intravenous anaesthetics; different combinations of anaesthetics; different patient positions (e.g. lateral, supine) and different durations of anaesthesia (e.g. 20, 30 or 45 minutes). We also planned to perform subgroup analyses for different inhalation anaesthetics; different types of surgery (e.g. open thoracotomy, thoracoscopic); different criteria and diagnoses for admission to critical care units and the different units involved. Finally, we planned to perform subgroup analyses for studies of participants in intensive care compared with studies of participants undergoing surgery and for the criteria used to diagnose adverse events. However, the number of studies was insufficient for performance of any of these subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to perform sensitivity analyses to explore the causes of heterogeneity and the robustness of the results by means of the following factors:<BR/>
</P>
<UL>
<LI>Trials with low risk of bias versus those with high risk of bias; and</LI>
<LI>Rates of withdrawal for each outcome (&lt; 20% vs greater than and/or equal to 20%).</LI>
</UL>
<P>However, the planned analyses could not be carried out because of lack of relevant data in the included studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY_DESCRIPTION MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.<I>
<B>
<BR/>
</B>
</I>
</P>
<SEARCH_RESULTS MODIFIED="2017-02-14 11:45:05 +0000" MODIFIED_BY="Jane Cracknell">
<P>We identified 2099 citations from the database searches (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for search results). After screening by title and abstract, we obtained full-paper copies for 46 citations that were potentially eligible for inclusion in the review. Of these, 36 did not fulfil our inclusion criteria and were excluded for the reasons described in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). For the first update of the review in 2012, 705 references (post de-duplication) were identified by the searches. We selected 12 references for careful reading and obtained them in full text when available. After assessing the full articles, we included 11 studies (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>) and added one study (<LINK REF="STD-Celik-2009" TYPE="STUDY">Celik 2009</LINK>) to the exclusion table. </P>
<P>We reran the search on February 7, 2017. The new search identified 1093 citations, and there were four potential included studies (<LINK REF="STD-Erturk-2014" TYPE="STUDY">Erturk 2014</LINK>; <LINK REF="STD-Hammouda-2013" TYPE="STUDY">Hammouda 2013</LINK>; <LINK REF="STD-Poto_x010d_nik-2014" TYPE="STUDY">Poto&#269;nik 2014</LINK>; <LINK REF="STD-Wakabayashi-2014" TYPE="STUDY">Wakabayashi 2014</LINK>). We will deal with the pending studies of interest when we update the review. Potential new studies of interest were added to a list of '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>' and will be incorporated into the formal review findings during the review update.</P>
<P> See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-07-01 14:59:00 +0100" MODIFIED_BY="[Empty name]">
<P>We included 20 studies (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>) in this review. These studies enrolled a total of 850 participants (please see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table).</P>
<SUBSECTION>
<HEADING LEVEL="3">Design of the studies</HEADING>
<P>All included studies claimed to be randomized controlled trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of study participants</HEADING>
<P>
<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK> and <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK> included healthy participants with American Society of Anesthesiology (ASA) physical status one and two (ASA I and II) who were scheduled for thoracotomy, video-assisted thoracoscopic surgery (inside the right hemithorax) and lobectomy, respectively. <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK> and <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK> included less healthy participants (ASA III). <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK> evaluated adults with ASA status I to III scheduled to undergo elective thoracic surgery with lung resection performed through thoracotomy or thoracoscopy. <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> did not specify ASA status, but this study assessed participants scheduled for elective lung surgery in the lateral position. <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK> included participants with ASA status I and II requiring OLV during anaesthesia for selective thoracic surgery. <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> included participants with ASA physical status I and II between 20 and 60 years of age scheduled to undergo thoracoscopic surgery or oesophageal surgery, with limited lung trauma but lengthy OLV. <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK> assessed only participants scheduled for elective thoracic procedures in the lateral position. <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK> assessed participants between 18 and 70 years of age who were undergoing lobectomy requiring OLV, with ASA I to III status. <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK> assessed participants with ASA grade I to III status for elective lobectomy. <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK> assessed participants scheduled for open thoracic surgery and OLV. In <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>, participants were included if ASA grade I to III and scheduled for thoracic surgery, with limited lung trauma but lengthy OLV. The other studies did not report ASA physical status but included participants scheduled for various thoracic operations (<LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>), major thoracic surgery (<LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>) and elective lung resection for carcinoma (<LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of intervention</HEADING>
<P>Studies compared one or more inhalation anaesthetics (sevoflurane, desflurane, isoflurane, halothane, enflurane) with one of three intravenous anaesthetics (propofol, ketamine, thiopental) for maintaining anaesthesia during one-lung ventilation. Most studies used one of these intravenous drugs (or etomidate) to induce anaesthesia in all participants, including those in whom inhalation agents were used to maintain anaesthesia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of outcome measures and duration of follow-up</HEADING>
<P>Studies reported a range of intraoperative physiological measurements, including haemodynamic and blood gas variables, as well as concentrations of inflammatory mediators.</P>
<P>
<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK> also reported adverse events for five postoperative days. <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> reported postoperative cognitive function.</P>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Awaiting assessment</I>
</HEADING>
<P>
<LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> is an ongoing trial, and we will include its final analysis in the next update of this review.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>We excluded 37 studies; see the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for full details.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>We reran the search in February 2017 and found four potential studies of interest. There are four studies awaiting classification (<LINK REF="STD-Erturk-2014" TYPE="STUDY">Erturk 2014</LINK>; <LINK REF="STD-Hammouda-2013" TYPE="STUDY">Hammouda 2013</LINK>; <LINK REF="STD-Poto_x010d_nik-2014" TYPE="STUDY">Poto&#269;nik 2014</LINK>; <LINK REF="STD-Wakabayashi-2014" TYPE="STUDY">Wakabayashi 2014</LINK>). These studies will be incorporated into the formal review findings during the review update. For further details of the studies see the table <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>) did not describe the procedures for random group allocation and allocation concealment.</P>
<P>
<LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> used a random table for allocation, and another anaesthesiologist, who was not involved with the study, performed the allocation concealment.</P>
<P>
<LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> used a computer-generated sequence and envelopes to conceal the sequence.</P>
<P>Two studies (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>) performed a block randomization, generated by computer, and the sequence was concealed by sealed opaque envelopes.</P>
<P>Three studies (<LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008;</LINK> <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>) reported only the generation of the allocation sequence (computer-generated random numbers) but did not describe the method used to conceal the sequence.</P>
<P>
<LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK> used a computer-generated randomization list, but the authors did not conceal the sequence.</P>
<P>
<LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK> used a computer-generated random sequence, and the randomization list was password-protected and concealed in white sealed envelopes.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Thirteen studies (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>) did not describe whether participants, personnel or assessors of outcomes were blinded to treatment allocation.</P>
<P>Although the <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK> study did not report in the article whether there was blinding, this item was retrieved when the authors confirmed by email that only the assessors were blinded. This study did not report on the blinding of participants and personnel.</P>
<P>The <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> study reported that participants and assessors were blinded, but investigators were not.</P>
<P>In two studies (<LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>), the anaesthesiologist who assessed the study data was blinded to the group assignments, but the studies did not report on blinding of participants and personnel. Participants from <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> were also blinded to treatment allocation.</P>
<P>In two studies (<LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>), all measurements were made by the same observer, who was not blinded to the anaesthetic regimen used. The authors did not discuss blinding of participants and personnel.</P>
<P>
<LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK> reported that participants were blinded, but anaesthesiologists who provided the anaesthetic were not. However, the individuals who performed the immunological and pathohistological analyses were blinded to the study protocol.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Nine studies (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>) reported the number of withdrawals or dropouts.</P>
<P>In <LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>, all participants completed the follow-up. <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK> excluded one participant from each group because of hypotension that was treated with vasoactive drugs during induction of anaesthesia. <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK> reported 10 and six dropouts with sevoflurane and propofol, respectively. <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK> excluded four participants because of re-inflation of the nondependent lung. No drop-outs were reported in <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>. <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK> excluded one participant in the isoflurane group because of oxygen desaturation that did not resolve when the inspired oxygen concentration was increased. <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK> excluded 15 participants: eight and seven in the propofol and sevoflurane groups, respectively. <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK> excluded three participants because the duration of OLV was too short for sufficient data to be gathered. <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK> excluded 10 participants: three because oxygen saturation fell below 90% and seven because surgery required ventilation to both lungs. In <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>, two and four participants were withdrawn in the sevoflurane and propofol groups, respectively.</P>
<P>In <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>, reporting was complete.</P>
<P>
<LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> is an ongoing study: so far, less than 10% of participants have been excluded.</P>
<P>The other eight studies did not report withdrawals and drop-outs (<LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-07-01 15:00:39 +0100" MODIFIED_BY="[Empty name]">
<P>No evidence of selective reporting was noted in the following included studies (<LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>). We could not determine whether selective reporting occurred in <LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; and <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-07-01 15:00:46 +0100" MODIFIED_BY="[Empty name]">
<P>No evidence of other biases was found in any of the included studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>With the exception of <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>, who reported results from oxygen delivery, all other studies included in the original review (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>) did not report on any of the outcomes listed in the protocol. Hence it was not possible to carry out a meta-analysis of studies from the original review. However, the new trials (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007)</LINK> reported on adverse postoperative outcomes and death.</P>
<SUBSECTION>
<HEADING LEVEL="3">Propofol versus sevoflurane</HEADING>
<P>No differences in rates of postoperative adverse events were reported by two studies (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>).</P>
<P>
<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK> reported no deaths one month after surgery (0/27 and 0/27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Propofol versus isoflurane</HEADING>
<P>No adverse postoperative outcomes were described in <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> (0/15 and 0/15).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-07-01 15:01:47 +0100" MODIFIED_BY="[Empty name]">
<P>This review examined the effectiveness and safety of intravenous versus inhalation anaesthesia for one-lung ventilation. We included 20 studies with a total of 850 participants and a mean of 42 participants per study (range 18 to 80), although most of the included studies evaluated between 30 and 40 participants. We did not find any randomized controlled trial that reported on participant outcomes. The quality of the included studies was very poor; as a result, it was not possible to use analytical methods such as meta-analysis and exploration of heterogeneity (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-07-01 15:01:52 +0100" MODIFIED_BY="[Empty name]">
<P>Because of our comprehensive search strategy and contact with experts in the field, we are confident that we have mapped most clinical trials comparing inhalation with intravenous drugs to maintain anaesthesia during one-lung ventilation.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-07-01 15:02:03 +0100" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included studies was generally unclear (<LINK REF="STD-Abay-2000" TYPE="STUDY">Abay 2000</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-El_x002d_Hakeem-2003" TYPE="STUDY">El-Hakeem 2003</LINK>; <LINK REF="STD-Gasowska-1999" TYPE="STUDY">Gasowska 1999</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pilotti-1999" TYPE="STUDY">Pilotti 1999</LINK>; <LINK REF="STD-Rees-1984" TYPE="STUDY">Rees 1984</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>; <LINK REF="STD-Spies-1991" TYPE="STUDY">Spies 1991</LINK>; <LINK REF="STD-Steurer-2007" TYPE="STUDY">Steurer 2007</LINK>; <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK>). Six studies were categorized as having low risk of bias (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>). Methodological aspects of four studies had a high risk of introducing bias: incomplete outcome data (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Reid-1996" TYPE="STUDY">Reid 1996</LINK>); poor allocation concealment (<LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>) and inadequate blinding of outcome assessment (<LINK REF="STD-Kellow-1995" TYPE="STUDY">Kellow 1995</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>A comprehensive search strategy was applied to identify all potential studies and their reports. However, although we emailed the first author of 9 studies (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Rutkowska-2009" TYPE="STUDY">Rutkowska 2009</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>; <LINK REF="STD-Schwarzkopf-2009" TYPE="STUDY">Schwarzkopf 2009</LINK>) to ask for clarification about methodological issues and to provide us with further information, only six (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK>; <LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>) responded.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review has compared the results of intravenous versus inhalation anaesthesia for participants undergoing OLV.</P>
<P>
<LINK REF="REF-Zeng-2010" TYPE="REFERENCE">Zeng 2010</LINK> conducted a systematic review to evaluate the effects of thoracic epidural anaesthesia combined with general anaesthesia on arterial oxygenation and intrapulmonary shunting during one&#8208;lung ventilation. However, no abstract was available. We have contacted the authors to request the full-text article.</P>
<P>A systematic review that focused on postoperative recovery and complications found that early recovery was faster in the desflurane and sevoflurane groups in adult participants, although the authors included only English studies published in the MEDLINE database (<LINK REF="REF-Gupta-2004" TYPE="REFERENCE">Gupta 2004</LINK>).</P>
<P>
<LINK REF="REF-Ozkose-2001" TYPE="REFERENCE">Ozkose 2001</LINK> performed an economic evaluation to assess sevoflurane and isoflurane anaesthesia on recovery and cost analyses after laminectomy and discectomy. The authors found that total intravenous anaesthesia was associated with highest intraoperative cost, faster recovery and the least frequent postoperative side effects.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-07-01 15:03:23 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-07-01 15:03:18 +0100" MODIFIED_BY="Jane Cracknell">
<P>Very little evidence is available from randomized controlled trials to show differences in participant outcomes for anaesthesia maintained by intravenous versus inhalation anaesthesia during one-lung ventilation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-07-01 15:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>Further research should be carried out only if participant outcomes are measured, including deaths and morbidity such as brain damage, heart failure, myocardial infarction, intraoperative awareness and requirement for blood transfusion.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank John Carlisle (content editor); Nathan Pace (statistical editor) and Marjolein de Wit, Kristin B Miller, Marialena Trivelli and Maurizio Solca (peer reviewers); as well as Laszlo L Szegedi, Durhane Wong-Rieger, Anne Lyddiatt, Karen Hovhannisyan, Jant Wale (consumer editor), and Jane Cracknell for their help and editorial advice during preparation of the 2008 review (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>) and of the first update of this review. We would also like to thank Thomas Schilling (<LINK REF="STD-Schilling-2011" TYPE="STUDY">Schilling 2011</LINK>), Junji Egawa (<LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>) and the authors of the <LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>; <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; and <LINK REF="STD-Pruszkowski-2007" TYPE="STUDY">Pruszkowski 2007</LINK> studies for their responses during the preparation of the first published review, as well as Mina Nishimori for translation and extraction data from the <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK> study. We also would like to thank Adriana Bassi, Wilson RO Milani and Delcio Matos for their contributions to the first version of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-07-03 22:53:44 +0100" MODIFIED_BY="Jane Cracknell">
<P>Norma SP Módolo: none known.</P>
<P>Marília P Módolo: none known.</P>
<P>Marcos A Marton: none known.</P>
<P>Enilze Volpato: none known.</P>
<P>Vinícius Monteiro Arantes: none known.</P>
<P>Paulo do Nascimento Junior: none known.</P>
<P>Regina P El Dib: paid scientific advisor on systematic review. RPED is also the director and co-ordinator of the Systematic Review Unit at FMB/Unesp.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-03 22:55:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Contributions to present update of review</HEADING>
<P>Conceiving the review: Norma SP Módolo (NSPM) Regina P El Dib (RPED).<BR/>Co-ordinating the review: RPED.<BR/>Undertaking manual searches: Enilze Volpato (EV).<BR/>Screening search results: Marília P Módolo (MPM), Marcos A Marton (MAM) and Paulo Nascimento Junior (PNJ).<BR/>Organizing retrieval of papers: EV.<BR/>Screening retrieved papers against inclusion criteria: NSPM, RPED, MPM and MAM.<BR/>Appraising quality of papers: NSPM, RPED, MPM and MAM.<BR/>Abstracting data from papers: NSPM, RPED, MPM and MAM.<BR/>Writing to authors of papers for additional information: MPM, MAM and Vinícius Monteiro Arantes (VMA).<BR/>Providing additional data about papers: MPM, MAM and VMA.<BR/>Obtaining and screening data on unpublished studies: MPM, MAM and PNJ.<BR/>Providing data management for the review: NSPM and RPED.<BR/>Entering data into Review Manager (<LINK REF="REF-RevMan-5.1" TYPE="REFERENCE">RevMan 5.1</LINK>): NSPM and RPED.<BR/>Analyzing RevMan statistical data: RPED.<BR/>Performing other statistical analyses not using RevMan: RPED.<BR/>Performing double entry of data: (data entered by person one: NSPM; data entered by person two: RPED).<BR/>Interpreting data: NSPM, PNJ and RPED.<BR/>Performing statistical analysis: RPED.<BR/>Writing the review: NSPM, PNJ and RPED.<BR/>Securing funding for the review: NSPM and RPED.<BR/>Performing previous work that was the foundation of the present study: NSPM and RPED.<BR/>Serving as guarantor for the review (one author): RPED.<BR/>Taking responsibility for reading and checking review before submission: NSPM and RPED.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Contributions to original review</HEADING>
<P>Adriana Bassi (AB) was responsible for the conception of this review. Regina P El Dib (RPED) and Délcio Matos (DM) were responsible for the design and overall co-ordination of the protocol. RPED and DM were responsible for co-ordinating the protocol. AB and Wilson Roberto Milani (WRM) were responsible for designing the search strategy, running searches, screening search results, obtaining papers, screening retrieved papers against the inclusion criteria, appraising the quality of papers and extracting data. AB wrote to authors of papers for additional information and to locate potentially relevant unpublished or ongoing studies. AB, RPED and WRM were responsible for data management in the review. AB, RPED, DM and WRM analysed and interpreted data and wrote up the results.<BR/>
</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-07-01 15:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of risk of bias in included studies section was updated from the review (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>) in the light of new guidelines published in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-02-14 17:09:36 +0000" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2017-02-14 12:05:18 +0000" MODIFIED_BY="Jane Cracknell">
<INCLUDED_STUDIES MODIFIED="2017-02-14 12:05:18 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Abay-2000" MODIFIED="2017-02-14 12:05:18 +0000" MODIFIED_BY="Jane Cracknell" NAME="Abay 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-02-14 12:05:18 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abay G, Izgi F, Coruh T, Macika H, Dogusoy I, Aykac Z</AU>
<TI>The effects of sevoflurane on hypoxic pulmonary vasoconstriction during one-lung ventilation in thoracic surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2000</YR>
<VL>84 Suppl 1</VL>
<PG>A27</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654897"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654896"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-2001" MODIFIED="2017-02-14 11:50:24 +0000" MODIFIED_BY="Jane Cracknell" NAME="Beck 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-14 11:50:24 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beck DH, Doepfmer UR, Sinemus C, Bloch A, Schenk MR, Kox WJ</AU>
<TI>Effects of sevoflurane and propofol on pulmonary shunt fraction during one-lung ventilation for thoracic surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2001</YR>
<VL>86</VL>
<PG>38-43</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:50:24 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654899"/><IDENTIFIER MODIFIED="2017-02-14 11:50:24 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="11575407"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654898"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Conno-2009" MODIFIED="2012-11-26 18:18:54 +0000" MODIFIED_BY="[Empty name]" NAME="De Conno 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-26 18:18:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D, et al</AU>
<TI>Anesthesic-induced improvement of the inflammatory response to one-lung ventilation</TI>
<SO>Anesthesiology</SO>
<YR>2009</YR>
<VL>1106</VL>
<PG>1316-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654901"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654900"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egawa-2009" MODIFIED="2013-07-01 15:25:40 +0100" MODIFIED_BY="[Empty name]" NAME="Egawa 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-07-01 15:25:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egawa J, Kawaguchi M, Inoue S, Nishiwada T, Furuya H</AU>
<TI>Cerebral oxygen balance and postoperative cognitive function in patients undergoing lung surgery with one lung ventilation under propofol or sevoflurane anesthesia</TI>
<SO>Journal of Neurosurgical Anesthesiology</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>4</NO>
<PG>408-9</PG>
<CY>New Orleans, LA United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654902"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Hakeem-2003" NAME="El-Hakeem 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abd El-Hakeem EE, Mohamed MS, Ali SM, El-Minshawy AM</AU>
<TI>Haemodynamic and pulmonary shunt fraction changes with sevoflurane or propofol anaesthesia during one-lung ventilation for thoracic surgery</TI>
<SO>Egyptian Journal of Anaesthesia</SO>
<YR>2003</YR>
<VL>19</VL>
<PG>233-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654905"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654904"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuoka-2009" MODIFIED="2011-12-26 18:38:29 +0000" MODIFIED_BY="[Empty name]" NAME="Fukuoka 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-26 18:38:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuoka N, Iida H, Akamatsu S, Nagase K, Iwata H, Dohi S</AU>
<TI>The association between the initial end-tidal carbon dioxide difference and the lowest arterial oxygen tension value obtained during one-lung anesthesia with propofol or sevoflurane</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2009</YR>
<VL>23</VL>
<PG>775-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654906"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gasowska-1999" MODIFIED="2012-11-26 18:15:15 +0000" MODIFIED_BY="[Empty name]" NAME="Gasowska 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-11-26 18:15:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gasowska J, Brzezinski K, Przesmycki K, Nestorowicz A</AU>
<TI>Effects of halothane, isoflurane, and propofol on venous admixture during one-lung ventilation in patients undergoing thoracoscopic procedures</TI>
<SO>Medical Science Monitor</SO>
<YR>1999</YR>
<VL>5</VL>
<PG>929-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654909"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654908"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2008" MODIFIED="2011-11-13 20:28:31 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-13 20:28:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang CH, Wang YP, Wu PY, Chien CT, Cheng YJ</AU>
<TI>Propofol infusion shortens and attenuates oxidative stress during one lung ventilation</TI>
<SO>Acta Anaesthesiologica Taiwanica</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>4</NO>
<PG>160-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654911"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654910"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwata-2008" MODIFIED="2013-07-01 15:26:45 +0100" MODIFIED_BY="[Empty name]" NAME="Iwata 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-07-01 15:26:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwata M, Inoue S, Kawaguchi M, Takahama M, Tojo T, Taniguchi S, et al</AU>
<TI>Jugular bulb venous oxygen saturation during one-lung ventilation under sevoflurane- or propofol-based anesthesia for lung surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>71-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellow-1995" MODIFIED="2017-02-14 11:50:53 +0000" MODIFIED_BY="Jane Cracknell" NAME="Kellow 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-02-14 11:50:53 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kellow NH, Scott AD, White SA, Feneck RO</AU>
<TI>Comparison of the effects of propofol and isoflurane anaesthesia on right ventricular function and shunt fraction during thoracic surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1995</YR>
<VL>75</VL>
<PG>578-82</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:50:53 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654915"/><IDENTIFIER MODIFIED="2017-02-14 11:50:53 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7577284"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654914"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pilotti-1999" MODIFIED="2017-02-14 11:50:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Pilotti 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-02-14 11:50:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pilotti L, Torresini G, Crisci R, De Sanctis A, De Sanctis C</AU>
<TI>Total intravenous anesthesia in thoracotomy with one-lung ventilation</TI>
<TO>Anestesia totalmente endovenosa nella toracotomia con ventilazione monopolmonare</TO>
<SO>Minerva Anestesiologica</SO>
<YR>1999</YR>
<VL>65</VL>
<PG>483-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:50:58 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654917"/><IDENTIFIER MODIFIED="2017-02-14 11:50:58 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10479834"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654916"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pruszkowski-2007" MODIFIED="2013-07-02 14:35:52 +0100" MODIFIED_BY="[Empty name]" NAME="Pruszkowski 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-02 14:35:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pruszkowski O, Dalibon N, Moutafis M, Jugan E, Law-Koune JD, Laloe PA</AU>
<TI>Effects of propofol vs sevoflurane on arterial oxygenation during one-lung ventilation</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2007</YR>
<VL>98</VL>
<NO>4</NO>
<PG>539-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654918"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1984" MODIFIED="2011-12-26 18:39:45 +0000" MODIFIED_BY="[Empty name]" NAME="Rees 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-12-26 18:39:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rees DI, Gaines GY</AU>
<TI>One-lung anesthesia: a comparison of pulmonary gas exchange during anesthesia with ketamine or enflurane</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1984</YR>
<VL>63</VL>
<PG>521-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654921"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654920"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-1996" MODIFIED="2017-02-14 11:51:10 +0000" MODIFIED_BY="Jane Cracknell" NAME="Reid 1996" YEAR="1996">
<REFERENCE MODIFIED="2017-02-14 11:51:10 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reid CW, Slinger PD, Lenis S</AU>
<TI>A comparison of the effects of propofol-alfentanil versus isoflurane anesthesia on arterial oxygenation during one-lung ventilation</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>869-73</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:51:10 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654923"/><IDENTIFIER MODIFIED="2017-02-14 11:51:10 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8969391"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654922"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutkowska-2009" MODIFIED="2013-07-01 15:27:05 +0100" MODIFIED_BY="[Empty name]" NAME="Rutkowska 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-07-01 15:27:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rutkowska K, Werszner M, Misiolek H</AU>
<TI>Comparison of desfluran and propofol anaesthesia for one lung ventilation</TI>
<SO>Proceedings of the European Anaesthesiology Congress, EUROANAESTHESIA</SO>
<YR>2009</YR>
<PG>77-8</PG>
<CY>Milan, Italy</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654925"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654924"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schilling-2011" MODIFIED="2012-11-26 18:16:35 +0000" MODIFIED_BY="[Empty name]" NAME="Schilling 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-11-26 18:16:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schilling T, Kozian A, Senturk M, Huth C, Reinhold A, Hedenstierna G, et al</AU>
<TI>Effects of volatile and intravenous anesthesia on the alveolar and systemic inflamatory response in thoracic surgical patients</TI>
<SO>Anesthesiology</SO>
<YR>2011</YR>
<VL>115</VL>
<NO>1</NO>
<PG>65-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654927"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-21 23:53:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654926"/><IDENTIFIER MODIFIED="2011-08-21 23:53:51 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwarzkopf-2009" MODIFIED="2011-11-13 20:30:14 +0000" MODIFIED_BY="[Empty name]" NAME="Schwarzkopf 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-13 20:30:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwarzkopf K, Hueter L, Schreiber T, Preussler NP, Loeb V, Karzai W</AU>
<TI>Oxygenation during one-lung ventilation with propofol or sevoflurane</TI>
<SO>Middle East Journal of Anesthesiology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>3</NO>
<PG>397-400</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654929"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654928"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spies-1991" MODIFIED="2017-02-14 11:51:24 +0000" MODIFIED_BY="Jane Cracknell" NAME="Spies 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-02-14 11:51:24 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spies C, Zaune U, Pauli MH, Boeden G, Martin E</AU>
<TI>A comparison of enflurane and propofol in thoracic surgery</TI>
<TO>Vergleich von Enfluran und Propofol bei thoraxchirurgischen Eingriffen</TO>
<SO>Der Anaesthesist</SO>
<YR>1991</YR>
<VL>40</VL>
<PG>14-8</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:51:24 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654931"/><IDENTIFIER MODIFIED="2017-02-14 11:51:24 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2006722"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654930"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steurer-2007" MODIFIED="2017-02-14 11:51:30 +0000" MODIFIED_BY="Jane Cracknell" NAME="Steurer 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-02-14 11:51:30 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Steurer MP, Steurer MA, Spahn DR, Zalunardo MP, Feser M, Schmid ER</AU>
<TI>One-lung ventilation: effect of anesthetics on production of inflammatory mediators in the respiratory compartment</TI>
<SO>Proceedings of the American Thoracic Society International Conference</SO>
<YR>2007</YR>
<CY>San Francisco, California, USA</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654933"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654932"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamada-2008" MODIFIED="2011-12-26 18:40:49 +0000" MODIFIED_BY="[Empty name]" NAME="Yamada 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-26 18:40:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamada N, Nagata H, Sato Y, Tomoyasu M</AU>
<TI>Effects of propofol or sevoflurane on cerebral regional oxygen saturation (rSO2) during one-lung ventilation</TI>
<SO>The Japanese Journal of Anesthesiology</SO>
<YR>2008</YR>
<VL>57</VL>
<NO>11</NO>
<PG>1388-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654935"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654934"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-02-14 11:57:02 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-1998a" MODIFIED="2017-02-14 11:51:45 +0000" MODIFIED_BY="Jane Cracknell" NAME="Abe 1998a" YEAR="1998a">
<REFERENCE MODIFIED="2017-02-14 11:51:45 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abe K, Mashimo T, Yoshiya I</AU>
<TI>Arterial oxygenation and shunt fraction during one-lung ventilation: a comparison of isoflurane and sevoflurane</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998a</YR>
<VL>86</VL>
<PG>1266-70</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:51:45 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654937"/><IDENTIFIER MODIFIED="2017-02-14 11:51:45 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9620517"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654936"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-1998b" MODIFIED="2017-02-14 11:51:51 +0000" MODIFIED_BY="Jane Cracknell" NAME="Abe 1998b" YEAR="1998b">
<REFERENCE MODIFIED="2017-02-14 11:51:51 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abe K, Shimizu T, Takashina M, Shiozaki H, Yoshiya I</AU>
<TI>The effects of propofol, isoflurane, and sevoflurane on oxygenation and shunt fraction during one-lung ventilation</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998b</YR>
<VL>87</VL>
<PG>1164-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:51:51 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654939"/><IDENTIFIER MODIFIED="2017-02-14 11:51:51 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9806702"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654938"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benumof-1987" MODIFIED="2017-02-14 11:51:56 +0000" MODIFIED_BY="Jane Cracknell" NAME="Benumof 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-02-14 11:51:56 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Benumof JL, Augustine SD, Gibbons JA</AU>
<TI>Halothane and isoflurane only slightly impair arterial oxygenation during one-lung ventilation in patients undergoing thoracotomy</TI>
<SO>Anesthesiology</SO>
<YR>1987</YR>
<VL>67</VL>
<PG>910-5</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:51:56 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654941"/><IDENTIFIER MODIFIED="2017-02-14 11:51:56 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3688534"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654940"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1996" MODIFIED="2017-02-14 11:52:02 +0000" MODIFIED_BY="Jane Cracknell" NAME="Boldt 1996" YEAR="1996">
<REFERENCE MODIFIED="2017-02-14 11:52:02 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Müller M, Uphus D, Padberg W, Hempelmann G</AU>
<TI>Cardiorespiratory changes in patients undergoing pulmonary resection using different anesthetic management techniques</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>854-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:02 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654943"/><IDENTIFIER MODIFIED="2017-02-14 11:52:02 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8969390"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654942"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bovill-1984" MODIFIED="2017-02-14 11:52:07 +0000" MODIFIED_BY="Jane Cracknell" NAME="Bovill 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-02-14 11:52:07 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bovill JG, Warren PJ, Schuller JL, van Wezel HB, Hoeneveld MH</AU>
<TI>Comparison of fentanyl, sufentanil, and alfentanil anesthesia in patients undergoing valvular heart surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1984</YR>
<VL>63</VL>
<PG>1081-6</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:07 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654945"/><IDENTIFIER MODIFIED="2017-02-14 11:52:07 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6239571"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654944"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canet-1994" MODIFIED="2017-02-14 11:52:12 +0000" MODIFIED_BY="Jane Cracknell" NAME="Canet 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-02-14 11:52:12 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Canet J, Sanchis J, Zegri A, Llorente C, Navajas D, Casan P</AU>
<TI>Effects of halothane and isoflurane on ventilation and occlusion pressure</TI>
<SO>Anesthesiology</SO>
<YR>1994</YR>
<VL>81</VL>
<PG>563-71</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:12 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654947"/><IDENTIFIER MODIFIED="2017-02-14 11:52:12 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8092500"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654946"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsson-1987" MODIFIED="2017-02-14 11:52:17 +0000" MODIFIED_BY="Jane Cracknell" NAME="Carlsson 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-02-14 11:52:17 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson AJ, Bindslev L, Hedenstierna G</AU>
<TI>Hypoxia-induced pulmonary vasoconstriction in the human lung: the effect of isoflurane anesthesia</TI>
<SO>Anesthesiology</SO>
<YR>1987</YR>
<VL>66</VL>
<PG>312-6</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:17 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654949"/><IDENTIFIER MODIFIED="2017-02-14 11:52:17 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3826689"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654948"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celik-2009" MODIFIED="2012-10-10 20:15:54 +0100" MODIFIED_BY="John B Carlisle" NAME="Celik 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-10 20:15:54 +0100" MODIFIED_BY="John B Carlisle" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celik HK, Ustun FE, Celik B, Basoglu A</AU>
<TI>Effects of desflurane and sevoflurane on oxygenation and shunt fraction during one-lung ventilation and on recovery time</TI>
<SO>Turkiye Klinikleri Journal of Medical Sciences</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>5</NO>
<PG>1222-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654951"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654950"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cigarini-1990" NAME="Cigarini 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cigarini I, Bonnet F, Lorino AM, Harf A, Desmonts JM</AU>
<TI>Comparison of the effects of fentanyl on respiratory mechanics under propofol or thiopental anaesthesia</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1990</YR>
<VL>34</VL>
<PG>253-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654953"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654952"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dikmen-2003" MODIFIED="2017-02-14 11:52:27 +0000" MODIFIED_BY="Jane Cracknell" NAME="Dikmen 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-02-14 11:52:27 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dikmen Y, Eminoglu E, Salihoglu Z, Demiroluk S</AU>
<TI>Pulmonary mechanics during isoflurane, sevoflurane and desflurane anaesthesia</TI>
<SO>Anaesthesia</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>745-8</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:27 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654955"/><IDENTIFIER MODIFIED="2017-02-14 11:52:27 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12859465"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654954"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dupont-1999" MODIFIED="2017-02-14 11:52:32 +0000" MODIFIED_BY="Jane Cracknell" NAME="Dupont 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-02-14 11:52:32 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dupont J, Tavernier B, Ghosez Y, Durinck L, Thevenot A, Moktadir-Chalons N, et al</AU>
<TI>Recovery after anaesthesia for pulmonary surgery: desflurane, sevoflurane and isoflurane</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1999</YR>
<VL>82</VL>
<PG>355-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:32 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654957"/><IDENTIFIER MODIFIED="2017-02-14 11:52:32 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10434815"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654956"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Furugen-1989" NAME="Furugen 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Furugen C, Satoh K, Koh J, Sakaguchi Y, Yanagitani T, Kosaka Y</AU>
<TI>A-aDO2 during one lung ventilation under propofol anesthesia</TI>
<SO>Anesthesia and Resuscitation</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>21-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654958"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-1996" NAME="He 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>He X, Liu L, Tang Z, Zhao X</AU>
<TI>The effects of anesthesia with different concentrations of sevoflurane on venous admixture in unilateral lung ventilation</TI>
<SO>Bulletin of Hunan Medical University</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>5</NO>
<PG>442-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654961"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654960"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-1999" NAME="He 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>He XJ, Liu L, Chang YT, Zhou JM</AU>
<TI>Comparison of the effects of inhaling desflurane and isoflurane on pulmonary shunt (Qs/Qt) in one lung ventilation</TI>
<SO>Chinese Journal of Anesthesiology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>12</NO>
<PG>748-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654963"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654962"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koishi-1998" NAME="Koishi 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koishi K</AU>
<TI>The effect of isoflurane anesthesia and total intravenous anesthesia with propofol on SpO2 during one-lung anesthesia</TI>
<SO>Journal of the Medical Society of Toho University</SO>
<YR>1998</YR>
<VL>45</VL>
<PG>271-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654965"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654964"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koishi-1999" MODIFIED="2017-02-14 11:52:47 +0000" MODIFIED_BY="Jane Cracknell" NAME="Koishi 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-02-14 11:52:47 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koishi K, Miyazaki N, Ooe Y</AU>
<TI>Changes in SpO2 during total intravenous anesthesia combined with propofol and SpO2 during one-lung anesthesia ventilation</TI>
<SO>Masui</SO>
<YR>1999</YR>
<VL>48</VL>
<PG>53-6</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:47 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654967"/><IDENTIFIER MODIFIED="2017-02-14 11:52:47 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10036890"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654966"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-1998" NAME="Ma 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ma H, Wang JK, Xu GZ, Zhang L, Shen ZR</AU>
<TI>The effect of sevoflurane on lung shunt fraction during one-lung ventilation</TI>
<SO>Chinese Journal of Anesthesiology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>67-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654969"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654968"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merli-1991" MODIFIED="2017-02-14 11:52:55 +0000" MODIFIED_BY="Jane Cracknell" NAME="Merli 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-02-14 11:52:55 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Merli M, Amari B, Ferrante M, Gagliardone MP, Milazzo F, Oppizzi M, et al</AU>
<TI>Hemodynamic effects of propofol in patients undergoing pulmonary excision and in patients undergoing closed heart mitral valve surgery</TI>
<SO>Minerva Anestesiologica</SO>
<YR>1991</YR>
<VL>57</VL>
<PG>399-412</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:52:55 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654971"/><IDENTIFIER MODIFIED="2017-02-14 11:52:55 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1944963"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654970"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagel-1998" MODIFIED="2017-02-14 11:53:02 +0000" MODIFIED_BY="Jane Cracknell" NAME="Pagel 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-02-14 11:53:02 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pagel PS, Fu JL, Damask MC, Davis RF, Samuelson PN, Howie MB, et al</AU>
<TI>Desflurane and isoflurane produce similar alterations in systemic and pulmonary hemodynamics and arterial oxygenation in patients undergoing one-lung ventilation during thoracotomy</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998</YR>
<VL>87</VL>
<PG>800-7</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:02 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654973"/><IDENTIFIER MODIFIED="2017-02-14 11:53:02 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9768773"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654972"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pueyo-1994" MODIFIED="2017-02-14 11:53:06 +0000" MODIFIED_BY="Jane Cracknell" NAME="Pueyo 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-02-14 11:53:06 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pueyo JA, Pajuelo A, Fuentes R, Bustos A, Guerrero M, Munoz M</AU>
<TI>Effect of propofol on oxygenation and the pulmonary short-circuit during single-lung ventilation</TI>
<TO>Efecto del propofol sobre la oxigenacion y el cortocircuito pulmonar durante la ventilacion a un solo pulmon</TO>
<SO>Revista Española de Anestesiología y Reanimación</SO>
<YR>1994</YR>
<VL>41</VL>
<PG>27-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:06 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654975"/><IDENTIFIER MODIFIED="2017-02-14 11:53:06 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8016427"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654974"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1985" NAME="Rogers 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rogers SN, Benumof JL</AU>
<TI>Halothane and isoflurane do not decrease PaO2 during one-lung ventilation in intravenously anesthetized patients</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1985</YR>
<VL>64</VL>
<PG>946-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654977"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654976"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosso-1995" MODIFIED="2017-02-14 11:53:13 +0000" MODIFIED_BY="Jane Cracknell" NAME="Rosso 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-02-14 11:53:13 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosso TM, Aguado GR, Vivo M, Nunez M, Grau F</AU>
<TI>Cardiocirculatory stability and early extubation in patients undergoing thoracic surgery with propofol as the single anesthetic agent</TI>
<TO>Stabilità cardiocircolatoria ed estubazione precoce nei pazienti sottoposti a chirurgia toracica utilizzando propofol come agente anestetico unico</TO>
<SO>Minerva Anestesiologica</SO>
<YR>1995</YR>
<VL>61</VL>
<PG>183-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:13 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654979"/><IDENTIFIER MODIFIED="2017-02-14 11:53:13 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7478049"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654978"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-2000" MODIFIED="2017-02-14 11:53:18 +0000" MODIFIED_BY="Jane Cracknell" NAME="Saito 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-02-14 11:53:18 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saito M, Cho S, Morooka H, Hasuo H, Shibata O, Sumikawa K</AU>
<TI>Effects of sevoflurane compared with those of isoflurane on arterial oxygenation and hemodynamics during one-lung ventilation</TI>
<SO>Journal of Anesthesia</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>1-5</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:18 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654981"/><IDENTIFIER MODIFIED="2017-02-14 11:53:18 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="14564602"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654980"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Satoh-1998" MODIFIED="2017-02-14 11:53:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Satoh 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-02-14 11:53:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Satoh D, Sato M, Kaise A, Hagiwara Y, Saishu T, Hashimoto Y</AU>
<TI>Effects of isoflurane on oxygenation during one-lung ventilation in pulmonary emphysema patients</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1998</YR>
<VL>42</VL>
<PG>1145-8</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:23 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654983"/><IDENTIFIER MODIFIED="2017-02-14 11:53:23 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9834795"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654982"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shimizu-1997" NAME="Shimizu 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shimizu T, Abe K, Kinouchi K, Yoshiya I</AU>
<TI>Arterial oxygenation during one lung ventilation</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1997</YR>
<VL>44</VL>
<PG>1162-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654985"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654984"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sj_x00f6_gren-1995" MODIFIED="2017-02-14 11:53:32 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sjögren 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-02-14 11:53:32 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sjogren D, Sollevi A, Ebberyd A, Lindahl SG</AU>
<TI>Isoflurane anaesthesia (0.6 MAC) and hypoxic ventilatory responses in humans</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1995</YR>
<VL>39</VL>
<PG>17-22</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:32 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654987"/><IDENTIFIER MODIFIED="2017-02-14 11:53:32 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7725878"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654986"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slinger-1988" MODIFIED="2017-02-14 11:53:37 +0000" MODIFIED_BY="Jane Cracknell" NAME="Slinger 1988" YEAR="1988">
<REFERENCE MODIFIED="2017-02-14 11:53:37 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Slinger P, Triolet W, Wilson J</AU>
<TI>Improving arterial oxygenation during one-lung ventilation</TI>
<SO>Anesthesiology</SO>
<YR>1988</YR>
<VL>68</VL>
<PG>291-5</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:37 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654989"/><IDENTIFIER MODIFIED="2017-02-14 11:53:37 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3277487"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654988"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slinger-1995" MODIFIED="2017-02-14 11:53:44 +0000" MODIFIED_BY="Jane Cracknell" NAME="Slinger 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-02-14 11:53:44 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Slinger P, Scott WA</AU>
<TI>Arterial oxygenation during one-lung ventilation. A comparison of enflurane and isoflurane</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>82</VL>
<PG>940-6</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:44 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654991"/><IDENTIFIER MODIFIED="2017-02-14 11:53:44 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7717566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654990"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solares-1992" MODIFIED="2017-02-14 11:53:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Solares 1992" YEAR="1992">
<REFERENCE MODIFIED="2017-02-14 11:53:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Solares G, Castro A, Villanueva M, Garcia Izquierdo M, Buitrago PM</AU>
<TI>Effect of isoflurane on gas exchange and systemic and pulmonary hemodynamics in man during single lung ventilation</TI>
<TO>Efecto del isoflurano sobre el intercambio gaseoso y la hemodinamica sistemica y pulmonar en el hombre durante la ventilacion a un solo pulmon</TO>
<SO>Revista Española de Anestesiología y Reanimación</SO>
<YR>1992</YR>
<VL>39</VL>
<PG>221-6</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:53:50 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654993"/><IDENTIFIER MODIFIED="2017-02-14 11:53:50 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1513938"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654992"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steegers-1990" MODIFIED="2017-02-14 11:56:26 +0000" MODIFIED_BY="Jane Cracknell" NAME="Steegers 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-02-14 11:56:26 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steegers PA, Backx PJ</AU>
<TI>Propofol and alfentanil anesthesia during one-lung ventilation</TI>
<SO>Journal of Cardiothoracic Anesthesia</SO>
<YR>1990</YR>
<VL>4</VL>
<PG>194-9</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:56:26 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654995"/><IDENTIFIER MODIFIED="2017-02-14 11:56:26 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2131866"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654994"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Temp-1992" NAME="Temp 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Temp JA, Henson LC, Ward DS</AU>
<TI>Does a subanesthetic concentration of isoflurane blunt the ventilatory response to hypoxia?</TI>
<SO>Anesthesiology</SO>
<YR>1992</YR>
<VL>77</VL>
<PG>1116-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654997"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654996"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Keer-1989" NAME="Van Keer 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Keer L, Van Aken H, Vandermeersch E, Vermaut G, Lerut T</AU>
<TI>Propofol does not inhibit hypoxic pulmonary vasoconstriction in humans</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>284-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2654999"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2654998"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Leeuwen-1990" MODIFIED="2017-02-14 11:56:39 +0000" MODIFIED_BY="Jane Cracknell" NAME="Van Leeuwen 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-02-14 11:56:39 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Leeuwen L, Zuurmond WW, Deen L, Helmers HJ</AU>
<TI>Total intravenous anaesthesia with propofol, alfentanil, and oxygen-air: three different dosage schemes</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1990</YR>
<VL>37</VL>
<PG>282-6</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:56:39 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2655001"/><IDENTIFIER MODIFIED="2017-02-14 11:56:39 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2182204"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2655000"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1998" MODIFIED="2017-02-14 11:56:44 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wang 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-02-14 11:56:44 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang JY, Russell GN, Page RD, Jackson M, Pennefather SH</AU>
<TI>Comparison of the effects of sevoflurane and isoflurane on arterial oxygenation during one lung ventilation</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1998</YR>
<VL>81</VL>
<PG>850-3</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:56:44 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2655003"/><IDENTIFIER MODIFIED="2017-02-14 11:56:44 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10211007"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2655002"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" MODIFIED="2017-02-14 11:56:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wang 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-02-14 11:56:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang JY, Russell GN, Page RD, Oo A, Pennefather SH</AU>
<TI>A comparison of the effects of desflurane and isoflurane on arterial oxygenation during one-lung ventilation</TI>
<SO>Anaesthesia</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>167-73</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:56:50 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2655005"/><IDENTIFIER MODIFIED="2017-02-14 11:56:50 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10651681"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2655004"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamada-1990" MODIFIED="2017-02-14 11:56:56 +0000" MODIFIED_BY="Jane Cracknell" NAME="Yamada 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-02-14 11:56:56 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yamada M, Ochiai R, Takeda J, Nagano M</AU>
<TI>Does anesthetic technique affect the oxygenation during one lung anesthesia?</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1990</YR>
<VL>37</VL>
<PG>S164</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:56:56 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2655007"/><IDENTIFIER MODIFIED="2017-02-14 11:56:56 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2361279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2655006"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yondov-1999" MODIFIED="2017-02-14 11:57:02 +0000" MODIFIED_BY="Jane Cracknell" NAME="Yondov 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-02-14 11:57:02 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yondov D, Kounev V, Ivanov O, Prisadov G, Semerdjieva M</AU>
<TI>A comparative study of the effect of halothane, isoflurane and propofol on partial arterial oxygen pressure during one-lung ventilation in thoracic surgery</TI>
<SO>Folia Medica</SO>
<YR>1999</YR>
<VL>41</VL>
<NO>3</NO>
<PG>45-51</PG>
<IDENTIFIERS MODIFIED="2017-02-14 11:57:02 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2655009"/><IDENTIFIER MODIFIED="2017-02-14 11:57:02 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10658366"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2655008"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-02-14 12:00:13 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Erturk-2014" MODIFIED="2017-02-14 11:58:12 +0000" MODIFIED_BY="Jane Cracknell" NAME="Erturk 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-02-14 11:58:12 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erturk E, Topaloglu S, Dohman D, Kutanis D, Be&#351;ir A, Demirci Y, et al</AU>
<TI>The comparison of the effects of sevoflurane inhalation anesthesia and intravenous propofol anesthesia on oxidative stress in one lung ventilation</TI>
<SO>Biomed Research International</SO>
<YR>2014</YR>
<VL>360936</VL>
<PG>Epub 2014 Jan 5</PG>
<IDENTIFIERS MODIFIED="2017-02-13 18:32:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5093667"/><IDENTIFIER MODIFIED="2017-02-13 18:32:03 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24527444"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5093666"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammouda-2013" MODIFIED="2017-02-14 11:58:29 +0000" MODIFIED_BY="Jane Cracknell" NAME="Hammouda 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-02-14 11:58:29 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammouda SA, Rabbiha AAA, AlGanady AA, Ghoneima TA, Elsawyc MM, Youssif SA, et al</AU>
<TI>Immunomodulatory effect of propofol versus sevoflurane in patients undergoing thoracic surgery using one lung ventilation technique</TI>
<SO>Egyptian Journal of Chest Diseases and Tuberculosis</SO>
<YR>2013</YR>
<VL>62</VL>
<PG>731-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5093669"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5093668"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poto_x010d_nik-2014" MODIFIED="2017-02-14 11:59:22 +0000" MODIFIED_BY="Jane Cracknell" NAME="Poto&#269;nik 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-02-14 11:59:22 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poto&#269;nik I, Novak Jankovi&#263; V, &#352;ostari&#269; M, Jerin A, &#352;tupnik T, Skitek M, et al</AU>
<TI>Antiinflammatory effect of sevoflurane in open lung surgery with one-lung ventilation</TI>
<SO>Croatian Medical Journal</SO>
<YR>2014</YR>
<VL>55</VL>
<NO>6</NO>
<PG>628-37</PG>
<IDENTIFIERS MODIFIED="2017-02-13 18:29:52 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5093671"/><IDENTIFIER MODIFIED="2017-02-13 18:29:52 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25559834"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5093670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wakabayashi-2014" MODIFIED="2017-02-14 12:00:13 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wakabayashi 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-02-14 12:00:13 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wakabayashi S, Yamaguchi K, Kumakura S, Murakami T, Someya A, Kajiyama Y, et al</AU>
<TI>Effects of anesthesia with sevoflurane and propofol on the cytokine/chemokine production at the airway epithelium during esophagectomy</TI>
<SO>International Journal of Molecular Medicine</SO>
<YR>2014</YR>
<VL>34</VL>
<NO>1</NO>
<PG>137-44</PG>
<IDENTIFIERS MODIFIED="2017-02-13 18:33:34 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5093673"/><IDENTIFIER MODIFIED="2017-02-13 18:33:34 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24788377"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5093672"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-07-01 15:27:44 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-07-01 15:27:44 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Domino-1986" MODIFIED="2012-01-24 17:56:31 +0000" MODIFIED_BY="[Empty name]" NAME="Domino 1986" TYPE="JOURNAL_ARTICLE">
<AU>Domino KB, Borowec L, Alexander CM, Williams JJ, Chen L, Marshall C, et al</AU>
<TI>Influence of isoflurane on hypoxic pulmonary vasoconstriction in dogs</TI>
<SO>Anesthesiology</SO>
<YR>1986</YR>
<VL>64</VL>
<NO>4</NO>
<PG>423-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedlander-1994" MODIFIED="2008-06-06 23:50:06 +0100" MODIFIED_BY="Sara Margaryan" NAME="Friedlander 1994" TYPE="JOURNAL_ARTICLE">
<AU>Friedlander M, Sandler A, Kavanagh B, Winton T, Benumof J</AU>
<TI>Is hypoxic pulmonary vasoconstriction important during single lung ventilation in the lateral decubitus position?</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>1</NO>
<PG>26-30</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="8111940"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2004" MODIFIED="2012-05-28 19:07:12 +0100" MODIFIED_BY="[Empty name]" NAME="Gupta 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gupta A, Stierer T, Zuckerman R, Sakima N, Parker SD, Fleisher LA</AU>
<TI>Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a systematic review</TI>
<SO>Anesth Analg</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>3</NO>
<PG>632-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harpole-1999" MODIFIED="2012-12-19 13:51:19 +0000" MODIFIED_BY="[Empty name]" NAME="Harpole 1999" TYPE="JOURNAL_ARTICLE">
<AU>Harpole DH Jr, DeCamp MM Jr, Daley J, Hur K, Oprian CA, Henderson WG, et al</AU>
<TI>Prognostic models of thirty-day mortality and morbidity after major pulmonary resection</TI>
<SO>J Thorac Cardiovasc Surg</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>5</NO>
<PG>969-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-06-06 23:50:06 +0100" MODIFIED_BY="Sara Margaryan" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-07-01 15:27:19 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2011. www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loer-1995" MODIFIED="2012-01-24 17:57:50 +0000" MODIFIED_BY="[Empty name]" NAME="Loer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Loer SA, Scheeren TW, Tarnow J</AU>
<TI>Desflurane inhibits hypoxic pulmonary vasoconstriction in isolated rabbit lungs</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>83</VL>
<NO>3</NO>
<PG>552-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1984" MODIFIED="2008-06-06 23:50:06 +0100" MODIFIED_BY="Sara Margaryan" NAME="Marshall 1984" TYPE="JOURNAL_ARTICLE">
<AU>Marshall C, Lindgren L, Marshall BE</AU>
<TI>Effects of halothane, enflurane, and isoflurane on hypoxic pulmonary vasoconstriction in rat lungs in vitro</TI>
<SO>Anesthesiology</SO>
<YR>1984</YR>
<VL>60</VL>
<PG>304-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="6703386"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morgan-2001" MODIFIED="2013-07-01 15:27:27 +0100" MODIFIED_BY="Sara Margaryan" NAME="Morgan 2001" TYPE="BOOK_SECTION">
<AU>Morgan GE, Mikhail MS, Murray MJ, Larson CPJ</AU>
<TI>Anesthesia for thoracic surgery</TI>
<SO>Clinical Anesthesiology</SO>
<YR>2001</YR>
<PG>525-51</PG>
<EN>3rd</EN>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ozkose-2001" MODIFIED="2012-05-29 00:42:08 +0100" MODIFIED_BY="[Empty name]" NAME="Ozkose 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ozkose Z, Ercan B, Unal Y, Yardim S, Kaymaz M, Dogulu F, et al</AU>
<TI>Inhalation versus total intravenous anesthesia for lumbar disc herniation: comparison of hemodynamic effects, recovery characteristics, and cost</TI>
<SO>J Neurosurg Anesthesiol</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>4</NO>
<PG>296-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.1" MODIFIED="2013-07-01 15:27:44 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 5.1" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wada-1998" MODIFIED="2012-12-19 13:47:21 +0000" MODIFIED_BY="[Empty name]" NAME="Wada 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wada H, Nakamura T, Nakamoto K, Maeda M, Watanabe Y</AU>
<TI>Thirty-day operative mortality for thoracotomy in lung cancer</TI>
<SO>J Thorac Cardiovasc Surg</SO>
<YR>1998</YR>
<VL>115</VL>
<NO>1</NO>
<PG>70-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zeng-2010" MODIFIED="2012-05-29 00:35:29 +0100" MODIFIED_BY="[Empty name]" NAME="Zeng 2010" TYPE="JOURNAL_ARTICLE">
<AU>Zeng ZY, Pan LH, Lin F</AU>
<TI>Effects of thoracic epidural anesthesia combined with general anesthesia on arterial oxygenation and intrapulmonary shunting during one&#8208;lung ventilation: a systematic review</TI>
<SO>Chinese Journal of Evidence&#8208;Based Medicine</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>12</NO>
<PG>1450-55</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-06-08 19:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Bassi-2008" MODIFIED="2012-06-08 19:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bassi 2008" TYPE="COCHRANE_REVIEW">
<AU>Bassi A, Milani WRO, El Dib R, Matos D</AU>
<TI>Intravenous versus inhalation anaesthesia for one-lung ventilation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-01-06 15:37:12 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2012-01-06 15:37:12 +0000" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD006313.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-02-14 17:05:11 +0000" MODIFIED_BY="Jane Cracknell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-07-04 13:04:56 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-07-01 15:07:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abay-2000">
<CHAR_METHODS MODIFIED="2013-07-01 15:07:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: before intubation and 20 min after the onset of one-lung ventilation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>N: 20 participants. Sex: not reported. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: ASA I and II scheduled for thoracotomy. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Sevoflurane (2%) in group 1 versus propofol (1 mg/kg/h) and alfentanil (1.5 µg/kg/min) in group 2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:07:45 +0100" MODIFIED_BY="Dolores Matthews">
<P>Haemodynamic measurement and blood gas values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>Anaesthesia was induced with propofol in all participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:01:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beck-2001">
<CHAR_METHODS MODIFIED="2013-07-01 15:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: reported. Follow-up: after 30 min of TLV in the supine position; after 30 min stable OLV in the supine position and after opening of the pleura in the lateral decubitus position and before surgical manipulation of the lung (OLV)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>N: 40 participants. Sex: group 1: 6 females and 13 males; group 2: 7 females and 12 males. Age, y (mean): sevoflurane group 58 and propofol group 62. Setting: not reported. Inclusion criteria: subjects requiring OLV for thoracic surgery. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol was infused continuously at an initial rate of 9 mg/kg<SUP>-1</SUP>/h<SUP>-1</SUP> reduced to 6 mg/kg<SUP>-1</SUP>/h<SUP>-1</SUP> after 10 min and sevoflurane of 1.8 vol% (end-expiratory concentration)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="John B Carlisle">
<P>Cardiac index, mean arterial pressure, mean pulmonary artery pressure and PaCO<SUB>2</SUB>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:01:13 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Conno-2009">
<CHAR_METHODS MODIFIED="2013-07-01 15:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Period: not reported. Sample size: reported (40% difference in expression on inflammatory mediators at a 5% level of statistical significance and a power of 80%). Follow-up: five days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:10:19 +0100" MODIFIED_BY="[Empty name]">
<P>N: 70 randomly assigned, but 54 analysed. Sex: sevoflurane: 13 females and 14 males; propofol: 9 female and 18 males. Age, y (mean): sevoflurane group 55 and propofol group 58. Setting: not reported. Inclusion criteria: adults with ASA physical status I to III, scheduled to undergo elective thoracic surgery with lung resection performed through thoracotomy or thoracoscopy. Exclusion criteria: any dose of systemic or topical steroids, acute pulmonary or extrapulmonary infections, severe chronic obstructive pulmonary disease (Gold stage 2 to 4), history of recurrent pneumothoraces, pneumonectomy and/or lung volume-reduction surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (2.0 to 4.0 mcg/mL) or sevoflurane (1 MAC)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Inflammatory mediators in BALF; clinical postoperative outcomes (adverse events). Adverse events were defined as pulmonary infections necessitating antibiotic treatment; radiographically diagnosed pneumonia, atelectasis, effusion; fistula; reintubation; systemic inflammatory response syndrome; sepsis; acute respiratory distress syndrome; surgical revision and death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:12:44 +0100" MODIFIED_BY="[Empty name]">
<P>Anaesthesia was induced with propofol in all participants.</P>
<P>We contacted the authors of the study on 8 August 2011 to ask about the generation of allocation, allocation concealment and blind assessment procedures. Furthermore, we asked which exact target concentration of protocol participants received during anaesthesia maintenance. The authors replied on 21 September 2011</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egawa-2009">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: participants started to be recruited in March 2007 (ongoing study) [information retrieved by email from the authors]. Sample size: calculated the sample size using STATA<SUP>TM</SUP>, significance level of 5% and power of 80% [information retrieved by email from the authors]. Follow-up: 15 min after the termination of OLV</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>N: 60. Sex: not reported. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: participants ASA I to III scheduled for elective lung surgery in the lateral position. Exclusion criteria: pulmonary fibrosis or interstitial pulmonary disease; pregnant woman; mental disorder; MMSE score less than 24; moderate and severe liver dysfunction; moderate and severe renal dysfunction and blood coagulation abnormality [information retrieved by email from the authors]</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (n = 30) versus sevoflurane (n = 30), both combined with fentanyl and epidural anaesthesia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-13 22:51:14 +0000" MODIFIED_BY="[Empty name]">
<P>Regional cerebral oxygen saturation values, cognitive function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceedings. We contacted the main author on 13 November 2011 to ask about the full text. <LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK> informed us, the day after we emailed them, that the study is ongoing, so we sent another email to ask for further information about the study. The author replied on 16, 23 and 25 November, 2011</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El_x002d_Hakeem-2003">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: after 30 min of TLV; after 30 min of OLV in supine position and during OLV in the lateral position with the chest open and before surgical manipulation of the lungs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>N: 30. Sex: sevoflurane group: 6 males and 9 females; propofol group: 7 males and 8 females. Age, y (mean): sevoflurane group 50.7, propofol group 48.0. Setting: not reported. Inclusion criteria: participants requiring OLV for thoracic surgery. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Sevoflurane (1 MAC; n = 15) versus propofol (4 to 6 mg/kg/h; n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="Dolores Matthews">
<P>Haemodynamic variables, pulmonary shunt, mixed venous oxygen tension, arterial oxygen tension and arterial carbon dioxide tension</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>All participants were premedicated with oral midazolam (0.1 mg/kg) one hour before surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:50:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukuoka-2009">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Period: not reported. Sample size: based on the PaO<SUB>2</SUB> values measured in a previous study. Follow-up: 45 minutes of OLV</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]">
<P>N: 36 randomly assigned and 32 considered on the final analysis. Sex: 11 male and 5 female in propofol group, 7 male and 9 female in sevoflurane group. Age, y (mean): 67 in both groups. Setting: a university hospital. Inclusion criteria: participants with ASA status I and II requiring OLV during anaesthesia for selective thoracic surgery. Exclusion criteria: patients with severe cardiovascular or respiratory disease, morbid obesity (body mass index &gt; 30) or ASA physical status 3 or 4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (3 to 5 mg/kg/h) versus sevoflurane (1.4% to 1.6%)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]">
<P>Relationship between the initial ETCO<SUB>2</SUB> difference and the lowest PaO<SUB>2</SUB> value recorded during the first 45 minutes of OLV</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:50:19 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of the study by email on 21 July 2011 to ask whether the participants from the <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK> study were the same as those in their clinical trial. <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK> replied to the email on 26 July 2011, saying that "...the patients from both publications are not the same". We resent an email to ask if perhaps some of the participants were the same as in the <LINK REF="STD-Iwata-2008" TYPE="STUDY">Iwata 2008</LINK> study and to clarify whether participants and personnel were blinded to treatment allocation. The authors confirmed that participants from the two publications are not the same</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:19:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gasowska-1999">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: 10 min after induction of anaesthesia, when the participant was in the supine position and both lungs were ventilated; 10 min after a position shift (left lateral); 10 min of left OLV; 20 min of left OLV; 10 min ventilation of both lungs in the lateral position</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>N: 47. Sex: not reported. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: participants with ASA grades I and II, admitted for right-sided diagnostic or therapeutic elective VATS procedures. Exclusion criteria: patients with oxygen haemoglobin saturation &lt; 97% were immediately (preoperatively) excluded from the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>Halothane (0.4% to 0.6%), isoflurane (0.5% to 1.0%) or propofol (10-8-6 mg/kg/h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="Dolores Matthews">
<P>VATS procedures: resection of emphysematous bullae, lung biopsy, biopsy of a peripheral lung nodule, dissection of adhesions, resection of a pericardial cyst. Blood gas values, alveolar-arterial differences of oxygen partial pressure and Qs/Qt</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>The halothane and isoflurane groups also received nitrous oxide, whilst the propofol group received air</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2008">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Period: from August 2003 to July 2004 [information retrieved by email from the authors]. Sample size: 80% of power, 0.05 alpha, analysed by statistics specialist from their hospital [information retrieved by email from the authors]. Follow-up: only during the intraoperative period (T1: the first 2LV just before performing OLV; T2: near the end of OLV just before resuming 2LV, mostly 30 to 45 minutes after OLV; T3: 5 minutes after resuming 2LV and T4: 20 min after resuming 2LV)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>N: 30. Sex: 19 men and 11 women. Age, y (mean): propofol 44 and isoflurane 40. Setting: Taiwan University Hospital. Inclusion criteria: participants with ASA physical status I and II, 20 to 60 years of age, scheduled to undergo thoracoscopic surgery or oesophageal surgery, with limited lung trauma but lengthy OLV. Exclusion criteria: reoperation, steroid use, and antioxidant or immunosuppressant usage [information retrieved by email from the authors]</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (started at 10 mg/kg/h for 10 min and then switched to 8 mg/kg/h throughout the study; n = 15) versus isoflurane (1% to 2%; n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>Haemodynamic data; reactive oxygen species (ROS) production and total antioxidant status (TAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of the study on 13 November 2011 to ask about the following:</P>
<UL>
<LI>Study period (e.g. participants were recruited from February 1999 to June 2001);</LI>
<LI>Sample size calculation;</LI>
<LI>Generation of allocation;</LI>
<LI>Allocation concealment (i.e. sealed and opaque envelopes or by a third party);</LI>
<LI>Participants blinded to treatment allocation;</LI>
<LI>Drop-outs and how many participants remained in the final analysis;</LI>
<LI>Follow-up period;</LI>
<LI>Exclusion criteria; and</LI>
<LI>Any other bias in the study (i.e. conflict of interest, etc).</LI>
</UL>
<P>The authors replied on 16 November, 2011.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwata-2008">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Period: not reported. Sample size: based on the formula for normal distribution and assuming a type I error of 0.05 and a power of 0.95. Follow-up: 15 min after the termination of OLV</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>N: 52. Sex: 16 male and 10 female in propofol group; 17 male and 9 female in sevoflurane group. Age, y (mean): 61 in propofol group and 63 in sevoflurane group. Setting: university hospital. Inclusion criteria: participants scheduled for elective thoracic procedures in the lateral position. Exclusion criteria: renal insufficiency, liver dysfunction, cerebral infarction, documented coagulopathy or coronary or vascular disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Sevoflurane versus propofol combined with epidural anaesthesia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Haemodynamic variables, SpO<SUB>2</SUB> and blood gas analyses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of the study on 27 September 2011 to ask about the period of the study, the generation of allocation, allocation concealment and blind assessment of outcomes. Furthermore, we have asked whether this study evaluated the same participants as were included in <LINK REF="STD-Fukuoka-2009" TYPE="STUDY">Fukuoka 2009</LINK>. We are awaiting their reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:02:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kellow-1995">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: TLV, after 20 min of the allocated maintenance regimen during TLV; OLV, after 20 min of stable OLV before ligation or division of any pulmonary vessels or bronchi; end, during wound closure after at least 20 min of stable ventilation of all remaining lung tissue</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:02:39 +0100" MODIFIED_BY="[Empty name]">
<P>N: 22 (10 isoflurane group and 12 propofol group). Sex: isoflurane group: 3 female and 7 male; propofol group&#65293;2 female and 10 male. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: participants undergoing elective thoracotomy requiring OLV. Exclusion criteria: patients were excluded if they were younger than 18 or older than 75 years old, and if their cardiac rhythm was not predominantly sinus</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Isoflurane (1% to 1.5%) versus propofol (10 mg/kg/h, reducing at 10 min intervals to 8 and then 6 mg/kg/h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="Dolores Matthews">
<P>Cardiac index, heart rate, mean arterial pressure, pulmonary vascular resistance index, right ventricular ejection fraction, end-systolic and end-diastolic volume indices, shunt fraction and changes in haemodynamic data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:02:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pilotti-1999">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Sample size: not reported. Follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>N: 50. Sex: 43 female and 7 male. Age, y (mean): 63.8. Inclusion criteria: ASA II and III. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]">
<P>Group A propofol (4 to 7 mg/kg/h), fentanyl (1.5 to 2 µg/kg/h), atracurium (0.5 mg/kg/h) versus group B isoflurane (0.7% to 1.2%), fentanyl (1.2 to 1.5 µg/kg/h), atracurium (0.5 mg/kg/h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="Jane Cracknell">
<P>Pressure values, heart rate, PaO<SUB>2</SUB> and PaCO<SUB>2</SUB> levels, SPO<SUB>2</SUB> and PECO<SUB>2</SUB>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]">
<P>Premedication with diazepam 10 mg plus atropine 0.5 mg</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pruszkowski-2007">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre. Period: author could not provide the period of the study [information retrieved by email contact with the authors]. Sample size: two-tailed, alpha error of 5% and beta error of 20%. Follow-up: 40 min after initiation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>N: 80 randomly assigned and 65 completed the study. Sex: sevoflurane, 7 female and 26 male; propofol, 7 female and 25 male. Age, y (mean): 62 and 57, respectively, sevoflurane and propofol. Inclusion criteria: participants undergoing lobectomy requiring OLV, age between 18 and 70 years of age, ASA I to III and indication for thoracic epidural anaesthesia. Exclusion criteria: patients taking vasoactive drug at the time of selection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol versus sevoflurane</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was defined as the lowest PaO<SUB>2</SUB> during the study period. Other outcomes were measured: arterial blood gas analysis, end-tidal carbon dioxide concentration, heart rate, mean arterial pressure and BIS value</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of the study on 5 October 2011 to ask about the period of study, allocation concealment and blind assessment of outcome. The authors replied on the same day, saying that neither outcome assessment nor allocation was concealed. With regard to the period of the study, the authors could not provide this information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rees-1984">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: 5, 15, 30 and 45 min after establishment of OLV and again 15 min after re-establishment of two-lung ventilation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>N: 24 men. Age, y (mean): group one 55 and group two 60. Setting: not reported. Inclusion criteria: elective lung resections for carcinoma. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]">
<P>Ketamine 2 mg/kg followed by 0.65 mg/kg of d-tubocurare intravenously versus 1% to 3% enflurane</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="Dolores Matthews">
<P>Arterial blood samples, cardiac output, intrapulmonary shunt, cardiac index, oxygen delivery, oxygen consumption, stroke volume index, left and right ventricular stroke work indices, pulmonary vascular resistance and systemic vascular resistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]">
<P>All participants were given 10 mg of diazepam and 5 mg of droperidol intravenously before monitoring lines were inserted. The groups received different induction drugs (ketamine and thiopental) and different maintenance drugs (ketamine at 2 mg/kg/h vs enflurane 1% to 3%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:03:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reid-1996">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre: tertiary care university hospital. Period: not reported. Sample size: not reported. Follow-up: during two-lung ventilation and after 20 and 30 minutes of OLV with each anaesthetic technique</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>N: 30. Sex: not reported. Age, y (mean): for all participants 59. Setting: tertiary care university hospital. Inclusion criteria: participants undergoing thoracoscopic pulmonary surgery or oesophageal surgery. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="[Empty name]">
<P>Participants received either propofol-alfentanil infusion anaesthesia or one minimum alveolar concentration (MAC) of isoflurane during the initial period of two-lung ventilation and the first 30 minutes of OLV and then were switched to the other anaesthetic for the duration of OLV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="Dolores Matthews">
<P>Arterial blood gases and haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:03:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rutkowska-2009">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: 30 min after start of OLV</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>N: 40. Sex: not reported. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: participants with ASA physical status I to III scheduled for elective lobectomy. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (n = 20) versus desflurane (n = 20) combined with thoracic anaesthesia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>Haemodynamic and respiratory parameters, stroke volume and cardiac index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceedings. We contacted the main author on 5 October 2011 to ask about the full text. We are awaiting the reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-02 14:34:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schilling-2011">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Period: November 2006 to June 2008 [information retrieved by email from the authors]. Sample size: reported; on the basis of previous studies, significance level of 5% and power of 80%. Follow-up: 30 min after the surgical procedure</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>N: 63. Sex: 41 male and 22 female. Age, y (mean): 64 for propofol group, 60 for desflurane group and 63 for sevoflurane group. Setting: Otto-von-Guericke-Universty Magdeburg. Inclusion criteria: participants scheduled for open thoracic surgery and OLV. Exclusion criteria: persistent tobacco abuse, body mass index greater than 35 kg/m<SUP>2</SUP>, history of treatment with immunodepressant drugs in the 6 weeks before surgery, cardiac failure (New York Heart Association greater than II), clinically relevant obstructive or restrictive lung disease (vital capacity or forced expiratory volume in 1 s &lt; 50% of predicted value), pulmonary hypertension (mean pulmonary arterial pressure greater than 25 mm Hg) or preexisting coagulation disorders and participants with evidence of pulmonary or systemic infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (4 mg/kg/h) or sevoflurane (1 MAC)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>Cytokine concentrations (concentrations of TNF-a and IL-1b, IL-6, IL-8, IL-10 and IL-12 p70 in bronchoalveolar lavage fluids and serum samples), ventilation and gas exchange data and haemodynamic data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 14:34:35 +0100" MODIFIED_BY="[Empty name]">
<P>Anaesthesia was induced with propofol in all participants</P>
<P>We contacted the authors of the study on 5 October 2011 to ask about the period of the study, allocation concealment and blind assessment of outcome. The authors answered our queries.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwarzkopf-2009">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre. Period: not reported. Sample size: not reported. Follow-up: 30 min after beginning of OLV</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:46 +0100" MODIFIED_BY="[Empty name]">
<P>N: 60 randomly assigned and 54 completed the study. Sex: sevoflurane male:female 19:9; propofol 16:10. Age, y (mean): sevoflurane 61 and propofol 57. Setting: University Hospital in Jena, Germany. Inclusion criteria: participants with ASA grade I to III scheduled for thoracic surgery, with limited lung trauma but lengthy OLV. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:46 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (range 3 to 6 mg/kg/h) versus sevoflurane (1 MAC)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:46 +0100" MODIFIED_BY="[Empty name]">
<P>Arterial blood gases, haemodynamic and respiratory parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:47 +0100" MODIFIED_BY="[Empty name]">
<P>In both groups, anaesthesia was induced with propofol.</P>
<P>We contacted the authors of the study on 13 November 2011 to ask about the following:</P>
<UL>
<LI>Study period (e.g. participants were recruited from February 1999 to June 2001);</LI>
<LI>Sample size calculation;</LI>
<LI>Generation of allocation;</LI>
<LI>Allocation concealment (i.e. sealed and opaque envelopes or by a third party);</LI>
<LI>Participants blinded to treatment allocation;</LI>
<LI>Exclusion criteria; and</LI>
<LI>Any other bias in the study (e.g. conflict of interest, etc).</LI>
</UL>
<P>We are awaiting the authors' reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:04:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spies-1991">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Single-centre or multicentre: not reported. Period: not reported. Sample size: not reported. Follow-up: during TLV; 15 min after induction in the supine position; 20 min after surgical opening of the chest in the lateral decubitus position; 20 min after start of OLV and after extubation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>N: 28. Sex: not reported. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: ASA risk groups II and III. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (10 mg/kg/h) versus enflurane (1 MAC)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Haemodynamics and arterial and mixed venous blood gases</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:04:12 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steurer-2007">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: not reported. Period: not reported. Sample size: not reported. Follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>N: 18 randomly assigned. Sex: not reported. Age, y (mean): not reported. Setting: not reported. Inclusion criteria: participants undergoing major thoracic surgery. Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (n = 9) versus sevoflurane (n = 9)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Inflammatory mediators</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceedings. We contacted the main author on 13 November 2011 to ask about the full text. We are awaiting the reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:04:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamada-2008">
<CHAR_METHODS MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Multicentre or single-centre: single-centre. Period: February 2007 to February 2008. Sample size: not reported. Follow-up: the end of surgery</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>N: 50. Sex: propofol (14 males and 11 females); sevoflurane (10 males and 15 females). Age, y (mean): propofol 72.0 and sevoflurane 66.8. Setting: university hospital. Inclusion criteria: ASA I or II, diagnosed with lung tumour and scheduled for lung lobectomy requiring OLV. Exclusion criteria: patients with cerebrovascular disease; patients with impaired pulmonary function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]">
<P>Propofol (2 to 3 mcg/mL, n = 25) versus sevoflurane (1% to 2%, n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:04:56 +0100" MODIFIED_BY="[Empty name]">
<P>Cerebral regional oxygen saturation during surgery; PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>, HR, mean arterial pressure, arterial pressure-based cardiac index, haemoglobin concentration, body temperature</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]">
<P>Article in Japanese, only the abstract was written in English. Mina Nishimori, a Cochrane review author, kindly translated and extracted data from the <LINK REF="STD-Yamada-2008" TYPE="STUDY">Yamada 2008</LINK> study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ASA = American Society of Anesthesiologists' grade; BALF = Bronchoalveolar lavage fluid; MAC = Minimum alveolar concentration; OLV = One-lung ventilation; PaO<SUB>2</SUB> = Arterial oxygen partial pressure; PaCO<SUB>2</SUB> = Arterial carbon dioxide tension; PECO<SUB>2</SUB> = End-tidal carbon dioxide partial pressure; Qs/Qt = Shunt fraction; RCT = Randomized controlled trial; ROS = reactive oxygen species; TAS = total antioxidant status; TLV or 2LV = Two-lung ventilation; T1 = Time 1; VATS = Video-assisted thoracic surgery.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Abe-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing isoflurane and sevoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Abe-1998b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing isoflurane and sevoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Benumof-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing halothane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Boldt-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing intravenous anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Bovill-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing intravenous anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Canet-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing halothane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Carlsson-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="John B Carlisle" STUDY_ID="STD-Celik-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="John B Carlisle">
<P>Randomized controlled trial of desflurane versus sevoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Cigarini-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing thiopental and propofol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Dikmen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series comparing inhalation anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Dupont-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized cross-over design comparing sevoflurane, desflurane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Furugen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating propofol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-He-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized clinical trial evaluating sevoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-He-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Evaluated only isoflurane and desflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koishi-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Koishi-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Retrospective study comparing intravenous anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Ma-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing halothane and sevoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Merli-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating propofol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Pagel-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing isoflurane and desflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Pueyo-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating propofol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Rogers-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing halothane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Rosso-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Prospective study with propofol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Saito-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized cross-over design comparing sevoflurane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Satoh-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Shimizu-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial evaluating isoflurane and sevoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Sj_x00f6_gren-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series comparing inhalation anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Slinger-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial comparing enflurane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Slinger-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Solares-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Steegers-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating intravenous anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Temp-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Van-Keer-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case series evaluating intravenous anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Van-Leeuwen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized controlled trial evaluating intravenous anaesthetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Wang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized cross-over design evaluating sevoflurane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Wang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Randomized prospective cross-over study evaluating desflurane and isoflurane</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Yamada-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Yondov-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Comparative controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-02-14 17:05:11 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Erturk-2014">
<CHAR_METHODS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Design: RCT. Multicentre or single-centre: single-centre. Setting: not reported. Period: not reported. Sample size: not reported. Follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>N: 44. Inclusion criteria: aged between 18 and 65, ASA physical status I or II, undergo- ing OLV/2LV for thoracic surgery. Exclusion criteria: patients with ASA score of III or more and severe metabolic, renal, or hepatic diseases, using cigarettes or antioxidant agents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Sevoflurane versus propofol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Mean arterial pressures, heart rate, blood gas analyses </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-13 18:56:44 +0000" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-02-14 17:04:57 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hammouda-2013">
<CHAR_METHODS MODIFIED="2017-02-14 17:04:57 +0000" MODIFIED_BY="Jane Cracknell">
<P>Design: RCT. Multicentre or single-centre: single-centre. Setting: Alexandria Main University Hospital. Period: not reported. Sample size: not reported. Follow-up: 2nd postoperative day </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>N: 40. Inclusion criteria: patients schedule to elective lung resection surgery through thoracotomy. Exclusion criteria: acute pulmonary or extra pulmonary infections; severe chronic obstructive pulmonary diseases, and history of recurrent pneumothoraces; pneumonectomy and lung volume reduction surgery; contraindications for epidural catheter insertio; patients on chemotherapy, radiotherapy, immunosuppressant drugs or corticosteroids; history of allergy to local anaesthetic drugs; and trauma patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Sevoflurane versus propofol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Systemic inflammatory response, pulmonary inflammatory response, C-reactive protein, leucocyte count, and recovery status </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-02-14 17:05:06 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Poto_x010d_nik-2014">
<CHAR_METHODS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Design: RCT. Multicentre or single-centre: single-centre. Setting: University Medical Centre Ljubljana. Period: 2009-2013. Sample size: significance level of 0.05 and a power of 80%, it was enough to have 16 patients in each group. Follow-up: 6 hours after surgery </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-14 17:05:03 +0000" MODIFIED_BY="Jane Cracknell">
<P>N: 40. Inclusion criteria: the study included patients aged 20-70 years with the American Society of Anesthesiologists (ASA) physical status I-III, scheduled for elective open lobectomy with OLV. Exclusion criteria: history of drug hypersensitivity, drug addiction, treatment with psychotropic drugs, severe psychiatric and central nerve system diseases, persistent tobacco abuse, autoimmune system diseases, diabetes mellitus, cardiac failure (New York Heart Association class greater than 2), clinically relevant obstructive and restrictive lung diseases (vital capacity or forced expiratory volume in 1 s lower than 50% of the predicted values), pulmonary hypertension (mean pulmonary arterial pres- sure greater than 25 mm Hg), pre-existing coagulation disorders, and history of treatment with immunosuppressant drugs in the 4 weeks before surgery. Patients with evidence of pulmonary or systemic infections (CRP serum concentration greater than 5 mg/L, leucocytosis greater than 10.0 gigaparticles/L or body temperature greater than 37°C) were also excluded, as well as the patients who had received perioperative blood derivatives, steroids, or NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Sevoflurane versus propofol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-14 17:05:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Inflammatory mediators (interleukins 6, 8, and 10, C-reactive protein [CRP], and pro-calcitonin) and clinical postoperative outcome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-02-14 17:05:11 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Wakabayashi-2014">
<CHAR_METHODS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Design: RCT. Multicentre or single-centre: single-centre. Setting: not reported. Period: not reported. Sample size: not reported. Follow-up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-14 17:05:11 +0000" MODIFIED_BY="Jane Cracknell">
<P>N: 20. Inclusion criteria: American Society of Anesthesiologists Physical Status category I-II, undergoing cervico-thoraco-abdominal three-field lymph node dissection through a right thoracotomy. Exclusion criteria: neurologic or psychiatric disease, cardiac disease classified as NYHA classes II-IV, preoperative severe impairment of respiratory function (such as a vital capacity of &lt;50% or a forced expiratory volume in 1 sec of &lt;50% of that predicted), and pre-existing coagulopathy or thrombocytopenia. Subjects were also excluded if they exhibited systemic or local active infections (either clinically defined or evidenced by elevated C-reactive protein levels, leukocytosis or body temperature of &gt;38&#778;C)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-14 11:47:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Sevoflurane versus propofol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-14 11:48:49 +0000" MODIFIED_BY="Jane Cracknell">
<P>Inflammatory cytokines and chemokine [tumour necrosis factor (TNF)-&#945;, interleukin (IL)-1&#946;, IL-6, IL-8, IL-10 and IL-12p70]</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:07:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:09:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>Computer-generated [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>Computer-generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>Random table [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>Computer-generated randomization list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>Computer-generated randomization schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>By lottery</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>Computer-generated software (i.e. randomization was done by EXCEL scripts, which deliver columns (according to the number of groups needed) of random numbers) [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:08:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:10:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>Envelopes [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>Sealed and opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>By another anaesthesiologist who was not involved in the study [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>No protection [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>Randomization list was password-protected and white sealed envelopes were used [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-08-22 19:21:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:08:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:10:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>Participants are blinded, but anaesthesiologists are not blinded to treatment allocation [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>Participants were blinded, but the anaesthesiologist was aware of the study objectives [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>Participants were blinded, but anaesthesiologists who provided the anaesthesia were not [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:08:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:10:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>Assessors were blinded [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>Yes [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>The anaesthesiologist who assessed the study data were blinded to group assignments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>Investigators responsible for analyses of ROC production and TAS level were blinded to the anaesthetic technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>After induction, all measurements were made by the same observer, who was not blinded to the anaesthetic regimen used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>No blinding [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>The persons who did the immunological/pathohistological analyses were blinded to the study protocol [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>All participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:10:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>Two participants, one from each group, were excluded from analysis because vasoactive drugs were given for hypotensive episodes during anaesthetic induction</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>The authors analysed in all participants the BALF outcome. Only in 27 participants (14 propofol, 13 sevoflurane) the investigators analysed all BALF, cells and blood</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>Few drop-outs so far, &lt;10% according to information retrieved by email from the authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>Only four participants were lost (these participants were excluded because of re-inflation of the nondependent lung)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>No drop-outs [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>One participant in the isoflurane group was eliminated from the study after arterial desaturation that did not respond to increasing concentration of inspired oxygen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>15 participants were lost: 20% and 17.5%, respectively, propofol and sevoflurane</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>Three participants were removed from the study because of the shortness of the period of OLV and hence failure to gather sufficient data (12.5%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>10 participants; in 3, the study protocol was terminated prematurely because of arterial oxygen desaturation &lt; 90%; in the other 7, the protocol was terminated because re-inflation of the nonventilated lung was required for surgical reasons before the study protocol could be completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>All enrolled participants completed the study successfully</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>A total of 6.7% and 13.4% of withdrawals in sevoflurane and propofol, respectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>No withdrawals/drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:08:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>Not reported (abstract)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:10:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>Not reported (abstract)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>Not reported (abstract)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported (abstract)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:08:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abay-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egawa-2009">
<DESCRIPTION>
<P>No conflict of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Hakeem-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-2009">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasowska-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>None of the authors had conflicts of interest [information retrieved by email from the authors]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iwata-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kellow-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pilotti-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pruszkowski-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rees-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reid-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutkowska-2009">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schilling-2011">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwarzkopf-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steurer-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 15:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-04-10 16:49:46 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TD COLSPAN="4">
<P>
<B>Intravenous compared with inhalation anaesthesia for one-lung ventilation</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>participants ventilated by one-lung</P>
<P>
<B>Settings: </B>
</P>
<P>
<B>Intervention: </B>intravenous anaesthesia</P>
<P>
<B>Comparison: </B>inhalation anaesthesia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Death (at one month)</B>
</P>
<P>Follow-up: 5 days (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0</B>
</P>
<P>(0 to 0)</P>
</TD>
<TD VALIGN="TOP">
<P>54 (1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse postoperative outcomes</B>
</P>
<P>Follow-up: 5 days (<LINK REF="STD-De-Conno-2009" TYPE="STUDY">De Conno 2009</LINK>); 20 minutes after resuming 2LV (<LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>) and 15 min after termination of OLV (<LINK REF="STD-Egawa-2009" TYPE="STUDY">Egawa 2009</LINK>).</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR1.56</B>
</P>
<P>(1.07 to 2.29)</P>
</TD>
<TD VALIGN="TOP">
<P>132 (3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-01-14 12:45:42 +0000" MODIFIED_BY="Karen Hovhannisyan"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-09 16:49:53 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2017-02-14 17:04:57 +0000" MODIFIED_BY="Jane Cracknell">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-02-13 19:24:28 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for the original review published in Issue 2, 2008 (<LINK REF="REF-Bassi-2008" TYPE="REFERENCE">Bassi 2008</LINK>).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbEAAAagCAYAAADh/WcBAACAAElEQVR42uy9D2RX7////yFJkkSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-02-14 17:04:57 +0000" MODIFIED_BY="Jane Cracknell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for the update published in 2013 and the updated search in 2017</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlsAAATuCAYAAAD6EuaNAACAAElEQVR42uydD2SW3///P0ySZEZm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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAdLElEQVR42u1da2wc13U+fMxrd0VyhmQtSo1hSmpaQP2ROpViyaJi
L60kapM4CRogcJyXgcpOnCYoEjSJC7hOf8SWEzl1DTuJbEDxK21gw6idh2VLWsdeKQ+qUFE0SgOH
lBQ54tIVOUNKJGd3Z7nsfc1rH+Ryubvapc+nx+zce849Z2bP3Htn9n5zABCIuqENdDwJiDrBasdz
gKgfMLwQGF4IDC8EAsMLgeGFwPBCIDC8EFcMnXgKagsLT0HgST2GV6uOB8077uRwcETg3AuB4YVA
YHghMLwQGF4tA7Phiog6hVecQI6kSlZdqWPbWMa2HlvGwzKK8dLSiwaGUd17r0QiMSFtbqpj20G8
KtU32b+vTtE90oL9nI29XSMGR+NsDqBfkxVyOcd7VJlsRiIKfYTrROWoQwsV+ZCtSkkmbkuKmqR1
Usyhkqoe510D+WdGlKjJFBSb1Km0SVEGrNUeIuTEeKvde2XbayferQof4uwPLedSrt1n7F6wZUVj
tmWqA15bjjrsK0aUiO8Ds6uxlgD6NFklx5WUZbUPpPnNGEeNmHttkgAuR7PROfI5Px4jm7iaWiA7
vc9n5V5amDr2uYHxS8NMuiuWOXITqRt1aF38pfFAJ3D1TOawzhSmuwFu1M7ZfhnANjmVp61aWYW2
Ck8f6/LagY5xmI1mp+dIL8P6md7neTm4dv/+OLP9MrU9zf1ibdFPPdp/z7uKupJRr/Z8YHYvjHLp
OTMbmQcYjmWPzAIcz2Ic1Tu86NwrNw2QngTzerJ/zqCb3KgxRXYy18JYmmynjKEdZwxtF9NQnOTW
DKkbAJNsnK1G4MeEnARDGmuFCufGBmy/DEA7w1uVmCacNYaGvHZg1AB7ErTr3aY+Jmyfde0ubCW2
s9y2aIF9sjLU0mTa82EMRnOeDxSWMcClbY0dpJTp20rEt+YwjsqgVkyheAJs4xLpvaY25fI7EnSf
/pOzbEP3yEdRyP6RgOr5+ONdF9lwSK5/yfEk6YYXunsJd0rNO4p9Bz0h+XAJlalNCwvcB6GsZAJ2
qU/U9rrJgE5AGwKKAach0JI5uJDbmYCpq522cwPcHxcW/uaY0+txMjTlS+T/W2HyUiB6TaBzmxNm
iZt9ae6+yGXypZKbAvKF7+aS4rHACV4ocIIp+2VPcFmqedgTOu6r3AoX/ZvD48T2YtDukMltzwab
FNptATep00Mhjx0wPyVuLeXX6Ig6N6HdShx+HLupBlwD04+R2fKxI3avX5TeDH10HNwCm9VCcTVp
vEAmZmo/6FGAkxqTPGGbNPZJX3ZI8yQ7t6Q0VmbzRuxN0EsmUKoDRyN+c7wdimOTdsaLSrXQ9i9P
k0Kb2VZSrg5pSydt/XJzv8oikvqgwZZfhTzuBu3f2Yf8b0dv4kfwI3LIp3HZSUO62Jk9JszsHgi0
eTKrttE5V0bOThVKr9sjs5HMltMkeM71KVRyunv99+nNf7f8Wb8TnJ4fJF94okfWL/M+N6NQG1M9
0oGoJyTaYX6sYz50rodStmUyk1pncNt/4uqQtq4jbb1iXyJBJl/FHkD0ynb4IcSM2s9bitzGDMT2
KMMzALtkjKM6z71qNYGr+CGIbVdrxfz4U7219Nr54NMGzr1Kz706QGsev8YXKpP78n92LLz6aLVW
9k/N/byWXnenvh7YS7c1rGNoVuS1wMnAd0zUFLgYOrAY2sJZab1OLQJwQQ4CwwuB4YVAYHghGgmc
2uOdYx1vbzC8mmI8aPlBJPjEchEHRwTOvRAYXggEhhcCwwuB4VVnmFe+aSSWtW54GXG6Uitell67
cXXE26V07+Yb+8FldO5eEY02ZmMYNU94ZUf6lqxfmsO6KvyG9036juXlVkCjPa9jb9c04WU6Vs77
OkzOVHU0yoNNabJ61OWwmhFZMz02LjB6ru3zcbs1OenqibJ+TVG4aFxX9tm2KtkBpi2Vj/OO55Sy
HQxF1mzGx41wZ8yoTD+lNMX2+bey4OXKnH8L/RHmk2fLliUtCYaMNNpyaPhq1XtiC+o/SjB4lv59
WJld960sdMvT3Tn4zan2dU/kzg4maM196+a6SM3ghTe+O8eeCLczGV2ai2oZGEyd3xvPCz3dgnVf
+DnkY5dn2xdYwxf+8LnOnvN/9cMF+MoRiJE6Lk+bJnjup4cgH5nr2jMK//bKdy8daGP25iHxp23w
rVikbUG4QGxFmK03qC2CwTfOH7ybSQtb0cj85WdycPRxxz++6lartrV6HIW4WP5q1Yb3XgdlkD1a
oDMKo+SryZ6R0gAvamDtdGvUMVYj2LgEtzCZzBic8ZmzXI9yYR9i/F2X7jplTO44YwyRvYcksB7y
5Dlu2QrQadqjLxL720HjLCKNc3RvP3Mx48qFbQH7dJFLC1vfzNk2pdE62E2VvWwau7zS/CiJ8xMp
o4ipSqqu+fTBnYmlOKxQUByi1zp9ud2ZRICKW46OS2m05h8vLHZfLKDRJp3labS8QNgauSEHiV2M
W+vBwt8cF+tCo60I2i8SiUTHabFHmaptLiFxY/tTlz05UQPBAuCc2KIyzoDthskXiswdD9Fx/ecO
xnwqdilIo6WfHJfhKHSLuL99rk/C1vb5iegwPsdoosuGslRBPSX27j8NWyQAaZNDivPSKF2/kRyh
NZTDKgUVuYy6BTaphWWcTZsL8XfdMdbxuLU0YNgoJpNBcK/B7gKkETDEcMd5u/JmR3HlvhCyxZ5o
wNv5GyiELc0wxklnrOGyk2YJr9wo+W/0K+KC/8R7lfR5gN9lYkcAorNfpd+5wiZQ53tZjQ8uczaz
z5kqKJvqkT5AQmjmiYHnisxN9exL+0Ruib0a4D+uAjhpS3PTxMqNyi2CmdutUN6uZd857crdm5Gc
MPd3VLP5ci5h62Vb7iGiVz2PcdQkc68mgDmQ3F7L9pxYatU02rU693or8hyNzFwtm3vw68HJF4bX
Wz286gpcDI002kacWgTgghwEhhcCwwuBwPBCNBI4tcc7xzre3mB4NXA8WMNDBdJoETj3QmB4IRAY
XggMLwSGV1UwaySDWBvhRZOaqf0lKK7xJdmptvzlkuVBPmw59Y1Le7cKPq1Q1RdL1CXlrlU0WUSj
xV+xK+u9EokJjS/eLGKRLkEr7Zr5VsnyIB+2nPqOOh+emS6VDG/42KVVtFl4LFYa++AKB0fDynv9
lc4YrKbG8snGvXyuTpSlggU3z2t86K+ZhsEYqUlNonlaiaxLRmWZZKl6kjFa+1SFZ6tVBGFVMFoh
qMvtCAItxG2mORKVIyPML1fHDOWLdfU4c5ZjsyRRz7SRYO7a+K5/CuSoZeoiR24yIqs9PL9tkjF3
D4Xac1SRjVbIJSVF6wNJQhptpXMvw2fV8nyyP9RS7hPZRZbPtVdK3cv3eZ5XkbsVplLqDwHeYzo0
Tyt0jIvyR7Rz81x818TzvQCzRzLTfwMsx2sP052NZE0+vLi63E6nPOGudO+foJlit01np2geMhiH
Oa5ztZJRn3Tb8vSs7IsepyNLs0nlUuo2v7zjaWrVzVHbMU7Vj4ocue95KctD/eljpF37R92fDbX3
2LjGPwm5J2OZlz8CIN+DcVRJeJHJ1zvu9/bOMgbrszyfLAVPy5o5Y7yT76dFnleOnDH6rJenleaE
5XhhbEDInDS6MkRpCLRR3hjnx0oO46KCr8vtqGPGSXc4MqgdVQKNEgrHDOjkOu8ag9EX/LaEngS7
Pd7hda/TwDfGVL+ce+b6Tvf8HLn2EFjXs0MfIj5mr72YDrX3TkPkqhVyP3DsrQcBXv8HjKMyCC6G
pjTR/kuZAIs0lE9WFFDOaGF2VvA4pubgtLYzEeCtBompVMDp//pXdwQFRm5YgFnGOQvrFtsBj+k6
8u481Skm1RbmlRU5bum2mFEbyFEr/o3scdPYlkqC6+sIOacn275ukhNzvZkY/ua4BI32YuGdVnsR
mdQrCOeYdRjHdGNb72sh6ROeyAgT6M5fG55Xb59PRe7kt5FhXb9108tQKyZB2+1UJFaCa0sRYs62
m1y9o5BRe6IwRy3D7jY54Nxxs6C9ftcjISfNvUlz2ppt2E1VeEHpHYWPHTbDNaECZRPox/ng+GvY
rHjlfbCFjBz5/2V5Wv1vp3Nzai/fvwlOEelbp7b2hr5BzTbavs8ne74utXPKM6wzO2nHmxlSHbK5
v5BrS6E68JpHbeykfPBB2CwXlDPfi/LjwiJn8grIp/rVkN4cnFaCcjSn7ScBTt+PcVTZ3EtOv1og
cDKrhNmpU477CpLc3mCe1zY5Q+ZK0du8ZLR3sGSwr9jXiIzB35Q/RKR3rAtmqyUy0Y9IczNsJ3rb
+kDV1M2K+5o3g9mxupV50bdQnWnSVq+cLnrkMdUj3esRsx+gnNw2JXuuoLzAdxfRv1wfyLquHbhk
hfR+pr5vKii3TpeHP0HuWXBqX8ncq2Lo2WKi4LKZZONVvxSuek0wN16S4on6nkKn60KFNNq33txr
5eEVcxY7oxeLiuXsMnpS1a8pWrbppa4EZzb4/pp6YLG3UhothhdilcDF0EijbcSpRQAuyEFgeCEw
vBAIDC9EI4FTe7xzrOPtDYZX840HLTKiLJSrQBotAudeCAwvBALDC4HhhcDwqgPMK2zHvEL+YHiV
ByXdRlIrJt0ayoNFZRsadLDCjhF1/Sxjf8OKstE+aGAY1aH3SiQm5Nv4p6Kq8lqz0S8Wle1s0MFy
O+b8G8vY37mibLQ75rG3q8vgaEwf8/qroyxnqxPd55Juexh/1tSUo/xy55zX+K530B0iJxipIvcr
Z9uaUc6L1RXltSSj25oPylH+7fVpCm3bkBmDNrlPVvtI9ZdYO7b8vs8nwWXXxo8qim0zf0R9vGfv
PtvLRisbrp/cHi0Xdhxtn+Fmo50SPvao+0S27JQW4dloXV+Yve3yKYyjusy9dJ8bcXh8hnFf73Mf
5ubHo3NE4l9SHxGySkbVXdJt5/MH5U6/O0hAj9Y1T2TkzMP0a19ITd/7/hTT35Gd5L8xzL6c2UFE
5qJZk7Q4vCN7ZJZU33dwshegO3r4nXuAsWuptcOpo8YA80fUQ/7pHd2u7Zvf9PzUpzMPX8PKhZ0e
5eF5V86QuI+L45/o5o4euBC52vNlzrP35ocwjmofXmTy9Rf+8/+7GA/19jHjnCjgeWS1j7osXG0M
Rj1uzu3XwpgSbCw3RimrROZmjelqGc7iVbeDxulB6SH4zPU0j6xhvwgg/13fVqJwuwTaxwCke5I3
p7064ovLixX1pMHP7HJNObbnpybBZ/hKa2HHYflthY9nuI9nWV5binuNScfzZZdnz8ZstOVQ/WJo
ypBI7kmX5NgWsXDBZ7MWMnAL2LauTJgUS6OiP0epqyKPrGCw0uoTGXD0bBvZMzfmoetiofqJTJgX
S310/QSXmRsi3/ouBZi2oWy0/bnczoRrr2Ia7dp6WFT+N8daZaMdyhff44fnue0h0q1nje58KvgQ
gLNtQzK83COxdi2+eAZYHtnohxmDVZvl1SRSpNmJn5A9w05FPlykXsjk+JQJxcxcYWdLONet8NFF
yvWua/HiWfDs4cy+LDr8tO0rxCA5wT2LDt3yv/Rf9F/T39kQLHAeTX9njAWhdpf06OU2Vk7Gwsfs
g8fb4MLs5W+kzsJ4ukN9JJbPBWXEv9zJRw1gL1Fqn/n2/UR27/88EDm5AOorf2bJeYjOdujtDqiX
H/jbxxfcuoC6qBd7xA5p6LeP2K6fuVzHoZdztFzYuf62y1G2T01zH93WyP9fcd5/kBW0z8wFfHkU
Ar1Xuq0GI0pLYLFsjRdS6VXNvWRnrKBsKqeEl/hYGeU5buO8oaRPelOtjJwlQXOsa+AxYNlfp+cv
R7hMeMGUdYMsuLPH1jHZuwzGoI3tkbsuUY6rnB6jfFZl+Bivi4b94fUCPMvs8znPz5M8By0pF3a+
xvLbcjnioxN+O1hEe69V6Auxl5Owm6r53KtiHLpzvqkO2dxwuabxMLJ7fNXZaNfq3Kve4dX1scc7
Zprs6rYPfrGWzcUuBucXGF5Io60jcDE00mgbcWoRgAtyEBheCAwvBALDC9FI4NQe7xzreHuD4bXG
x4P6uYM0WgReawgMLwQCwwuB4YXA8GoamFVVrVTFDFbh8tNaocErJipOYeALqumyQiIP5EpaC6vo
XjogUh6Zd2XJTilHRVlhVeXvtV9b/Uf919o3AktwbKvIZRtSCeSqJeXX8U+JcB7dYhRW5Wzs7Zpn
cBS5Y0cYb9YR+WS/Jw8bSZ5T1h6mOWeB8W6jnOMq8tCCLw8u/bZ/r2yzzLWc8arIh5Kcz+vlkCV1
h4ClllU4Q5bmw+XXF81V65Wz9noU0S6xMBLKdUsxognub58mD+s0Jzfl8krzmI22ieZe+dR0N8CN
2jmbc2spM3XfxI8z72flcNUzyjYmd/VM5jDn3W57Q+Sh9eRFN5IA+xdzPTQvbpblls2njn3uA+PH
aM5cK6vwzGu98sSngb58IDs9x9PfHslM85xINFetV87Is8+mRLs0foUt7i/FtguTvM05M/tfxPvh
GOPy9mcxjponvHjS2NzYgE3/h1HayZw0tHedZeUidywwhsQQX2asGqDxr9CV9+CckTJ+blmeV5ay
XjMSmJyBlhkz6O+A9iSI9Lc0Hy7nxeZeD5ZTXBtYNe/a4v6yqYSh8TZp3lwyaEuZJOXyvp7DOCqD
6oloVYEy1O5gm3ffQfd33wH7OxZg8C5wywfPw/72PP20e3Bw8PeMVvZu8ulcPijPyWFeM+T//Z0L
VNdrnqicZ5PPzm/AflIw9b3OzrcxFad3/6tvY8yy9nshUO77xv+6tu7wiGjkUyczbn5XaidKE98+
dOAPB5i/HtJNRiOrnzt1JqKtDj5vdihc4bDcsRBk0Lb5bFdPns/F3IyxRbllAzlkTSb7NpiM8f2u
fJdIC0lz1frlJTws8M1xH1lsBJnmze2dm9BuhULmL6IJnnt1bkmRIJc02PKrcEUvyx0L7G0Ah4jI
cQeOjrh5aIX8ccO8iUeVvMlRyOi5pTC3rEq0+PtVlFNAZXOTdobHzMLUzSIfLs1V65cnvRtAHrP3
F/nWDRp/MUb+t6N0fqgljR+R24jTuOyk6cJren6QfImJXtkuuNFvZ7lj6Qy7W/7sq4Ljqti8wxHy
sbkB2sPJ68FKx46SES5TmFt2qkc6wBm1Ux9SqOwMz4IrraccWHHU8q5gubLeVZbZp+JctzNqP3ct
etsAvfeM7lGGZwB2yRhHZYfmJqO21Dt3bOi514YLvatvZWpjjWm0LdJ/tCTPsd65Y0MwsrOrbyQm
BVeoYngFw6vppg2NjK7a/LhYEKH55jqfV9YdnJXWGEijbYqpPQLDC4HA8EJgeCHegsCpfY2BNFqk
0eJ4UM/DyeHgiMBrDYHhhUBgeCEwvBAYXlcKZgM0VqeHaObwciLKvi6fqFGY9XXDklluS+HuMhp6
rCq9MtloYzaGUSuEV5eSug++VrZ66RyxpfCb0hrmdVZVegKFVed17O1aIbzyY4Zx6SGaI1aO8G+M
MmlHGAXWFuRWzQFHc8tpV9KtuvJxmzFnadbbEcZ+FXTYeI8qG5QDq/TwjmfzCakqPeiPaJzD26+x
VLmGLGlJMJRNGEctEF6dg0cdupxQn86+xH9XuPpnmcltALYy5+axlf4InpLccoqOcU++f0LqJTpq
RmHhkBJ0WMiPx+YAtqkpsbQu+5Pq9CDzhxj363I0Mz0LMBtxzD0AP8Z0oa0QXm/88wejWorliBX8
WWc7aCqJBz9H7E/ugc8rbjnFqOHJnzfOkOB0RmGMft9nvAXwPC+uOmac5fu5rdXpwVnjIreanmRM
3G/mbJs4thXDqxyabK29ObjzxSVzxJob0mo6kKOW5Yr15EWyWHdTJi+u5FSnF8hG25fbnUnAyA05
SOwK8wMs/M0x15xvyFFMMGaOlcgRe8KfOxsdPfuDDFtXymHPE8xPc/ZrKWqynxe33axOD/pdiW6Y
fIFsts9PRIfxOUaLDI7pQcfslsiW82dpP8P5s9ImR3WDTL62yyt39YT8NbCJ1p2GLSLD3/HgqGVv
hmuSfI53ujo9mIe3cxpt7ohNGWyaYYwvkg0uO2mF8LLui63PnSdbniOWzopuVG6JAfyO5Yi9f4AW
/d/xm71yV0/Id+zL3UXq3qukz/MKKfh8y8+LK/+6Oj0Y1exz7MPMEwPP0WmaLfcQ0auexzhqjbnX
arA8AVfkxTU//oJUjV4Z1Dwb7RqaezX4DTn1xIWFJau7Fjt/+uqj9NP+qUxbNXpl8OfPPBAc4dvW
VnhVcTh5LXAykJhX2xEeTwFmo23AqUUALshBYHghMLwQCAwvRCOBU3u8c6zj7Q2G1xUaD9bwsIE0
WgTOvRAYXggEhhcCwwuB4fXWAK5AxfCqA4y9MktYW46zW4ZKi8DwqgCp+buypt63ZA5cigSeKgyv
lWO9NgSaluY8Wl2R/Ly28e69TMJRRUbaZERWegBsSdGSeOIwvCqBOkb+G8tyzm4+dYnntX2R8jY6
nmYSj40f5nmI3vNSNkKG0S/GMi8/iSeuDHC1anhqxUY9JcN4js8adENJjLTgWbagPn7fdpcNycVj
cNEOLLWveK39Wv5RqDl5jk0AlsnRvWvkUXN9PB5f9PZgu7v83OyO0TXl1mLXQB+eOBwcK0FmM/lv
sxSKuBBll1Jp+YcNbTJlsUlzb0Zm8cRheFWCCTsJSft3ACc8Jm3GgdcivsQcnOZU2kVplC43UW3j
hU/iiSuDNUREqwUOXJ48/7T1IImazgWRDz7X03Zhcl5ka4fBp578gdVB92aH7/zO6bOgt7c/ceCQ
30KlRLS2tXsSkYhWP+DUHqf2iAYBV6vWfGioqRiGFyIInGvgnSMCwwuB4YVAYHghMLwQGF4IBIYX
AsMLgeGFWBGsK6zfXA1geCGw90JgeCEQBcD1Xk0291oLwBePN+DcVhmeq73cm6ABHBwROPdCYHgh
EDi1R1yJ+xyc2tfj3lFnG73yabKnw7YrUvWn03p1tv3puF6xB7zK97qcUQyvmkcXP8nsb8XR5X4x
utirXDV0w1qNbV/dgko9sAqOtKxRnHs10cOM6h8JWHrNrouaWsPeq84dWTXjahWqVuEDt5Xb1iv2
QK/4gDG86tUhWfSvVfGdkzs2ku1KVcHTrNJ2UTtVeVBKB8OrngOemJmscIysQlVfte3VelBaB+de
zTE2Wqsc2lY/Luurn80V62B4NVEkVv9zeK1+SK/1D/L4WLX2oRJ8SlDZ6Q08dVqpatjoKhrQV+J8
qedeJXQsDC9EHa80HBwRdQSGFwLDC4HhhUBgeCEwvBBrAoEfhZDjgqgR9BLhhU/AELWBhYMjAude
CAwvBALDC4HhhVhb6Fx65t9695Toe9OHV2Gflm/hI8q1ku8FWfgWcXBEIDC8EE0eXlaFtUVyluWX
XqEfnqySxq2WOB7P93IuNfOprxURbbnXEbTaXLUJj0dvwVO/8sHRssSV5F0ZFvsjaoJXHJe0Cq4k
IeZLN7Qbc40Hj8bdWE19PNwWhPxv9lO/4t6r1JsILD1cE9x332rhESzDL75oeHzp/t9iZ3xfm/N4
qJ2Q8WY/9VUOjrol/hT0u3pRn1zUN+tXtL/WS9rWw9vmOh6r4MwXO9i8p76GLwHQAy+pWv506VZT
zMSWmPc2y/FUwLBt2lPfWdvzQK+eZV5NYAVeUnbl40sP+dSyx9Osrlb73Etn71HRq3lyEbgpaNjZ
t4oGDmuZpxbNejzWah4aNfzUd67wwPTyPatfw+MuLKlbXiWvaejgWGAt6Az9JHxq+uMp6Wczn/rA
SwD8q7uQu51vpZ+FC39zbCXfC39z1Jd7mNWkx6GX+TIQzf29QYutosDwaiW03AKd0uGVb+GvINfC
vi+uteuhc01cJOh7kwIX5CAwvBAYXggEhhcCwwuB4YVALI3ggwl8AxOifuGF719C4OCIwPBCIDC8
EBheCAwvBALDC4HhhUAgEMvj/wGPGxtFDr4rjgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-07-01 15:13:52 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAAOtCAIAAACOvHAFAAAvwUlEQVR42u3dvY4cx9nF8QUMGA42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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-06-11 16:03:23 +0100" MODIFIED_BY="Jane Cracknell"/>
<APPENDICES MODIFIED="2017-02-14 11:50:09 +0000" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2017-02-14 11:50:09 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2008-01-14 12:44:11 +0000" MODIFIED_BY="Karen Hovhannisyan">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-02-14 11:50:09 +0000" MODIFIED_BY="Jane Cracknell">
<P>
<B>CENTRAL, <I>The Cochrane Library</I>
</B>
</P>
<P>#1 OLV or one lung* or one-lung* or single-lung* or single lung or ((one lung*) near ventil*)<BR/>#2 anesth* or anaesth* or propofol* or diisopropylphenol or diprivan* or disoprivan or disoprofol or pofol or sevofluran* or sevorane orultane or desfluran* or suprane or isofluran*<BR/>#3 MeSH descriptor Anesthesia and Analgesia explode all trees<BR/>#4 MeSH descriptor Anesthesia explode all trees<BR/>#5 MeSH descriptor Anesthesia, Conduction explode all trees<BR/>#6 MeSH descriptor Anesthesia, Inhalation explode all trees<BR/>#7 MeSH descriptor Anesthesia, Closed-Circuit explode all trees<BR/>#8 MeSH descriptor Anesthesia, Intravenous explode all trees<BR/>#9 MeSH descriptor Anesthetics, Intravenous explode all trees<BR/>#10 MeSH descriptor Anesthetics, Dissociative explode all trees<BR/>#11 MeSH descriptor Anesthetics, Inhalation explode all trees<BR/>#12 (#2 OR #3 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)<BR/>#13 (#1 AND #12)</P>
<P>
<B>MEDLINE (Ovid SP)</B>
</P>
<P>1. (OLV or one?lung* or single?lung*).ti,ab. or ((one?lung* or single?lung*) adj3 ventil*).af.<BR/>2 . an?esth*.ti,ab. or (propofol* or diisopropylphenol or diprivan* or disoprivan or disoprofol or pofol or sevofluran* or sevorane or ultane or desfluran* or suprane or isofluran*).mp. or exp Propofol/ or explode Anesthetics-Inhalation/ or explode Anesthetics-Dissociative/ or explode Anesthetics-Intravenous/ or explode Anesthesia-Intravenous/ or explode Anesthesia-Closed-Circuit/ or explode Anesthesia-Inhalation/ or explode Anesthesia-Conduction/ or Anesthesia/ or explode Anesthesia-and-Analgesia/<BR/>3. 1 and 2<BR/>4. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.<BR/>5. 3 and 4</P>
<P>
<B>Embase (Ovid SP)</B>
</P>
<P>1. (OLV or one?lung* or single?lung*).ti,ab. or ((one?lung* or single?lung*) adj3 ventil*).af. (314)<BR/>2. an?esth*.ti,ab. or (propofol* or diisopropylphenol or diprivan* or disoprivan or disoprofol or pofol or sevofluran* or sevorane orultane or desfluran* or suprane or isofluran*).mp. or exp Propofol/ or anesthesia/ or analgesia/ or exp anesthesia-induction/ or exp inhalation-anesthesia/ or exp intravenous-anesthesia/ or anesthetic-agent/ (394435)<BR/>3. 1 and 2 (191)<BR/>4. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* or factorial* or placebo* or volunteer* or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*))).ti,ab.) not (animals not (humans and animals)).sh. (4024409)<BR/>5. 3 and 4</P>
<P>
<B>ISI Web of Science</B>
</P>
<P>#1 TS=OLV OR TS=(single SAME lung) or TS=(one SAME lung) or TS=(lung SAME ventil*)<BR/>#2 TS=anaest* or TS=anest* or TS=(Propofol* or diisopropylphenol or diprivan* or disoprivan or disoprofol or pofol or sevofluran* or sevorane or ultane or desfluran* or suprane or isofluran*)<BR/>#3 TS=((SINGL* or DOUBL* or TREBL* or TRIPL*) SAME (BLIND* or MASK*)) or TS=(RANDOM* or TRIAL* or CROSSOVER* or CROSS-OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) or TS=(clinical SAME trial*)<BR/>#4 #3 AND #2 AND #1</P>
<P>
<B>LILACS (BIREME)</B>
</P>
<P>"one" or "single" or "um" or "uno" or "solo" or "único" [Words] and "lung" or "pulmão" or "pulmón" [Words] and "ANESTHESIA" or "ANESTHESIA AND ANALGESIA" or "ANESTHESIA AND ANALGESIA/" or "ANESTHESIA, CLOSED-CIRCUIT" or "ANESTHESIA, CLOSED-CIRCUIT/" or "ANESTHESIA, CONDUCTION" or "ANESTHESIA, CONDUCTION/" or "ANESTHESIA, GENERAL/" or "ANESTHESIA, INHALATION" or "ANESTHESIA, INHALATION/" or "ANESTHETICS" or "ANESTHETICS, DISSOCIATIVE" or "ANESTHETICS, DISSOCIATIVE/" or "ANESTHETICS, GENERAL" or "ANESTHETICS, INHALATION" or "ANESTHETICS, INHALATION/" or "ANESTHETICS, INTRAVENOUS" or "ANESTHETICS, INTRAVENOUS/" or "Anestesia" or "Inhalation Do Anesthesia" or "Inhalación De la Anestesia" or "Conducción De la Anestesia" or "Condução Do Anesthesia" or "Intravenoso" or "Anestésicos" or "Anestésico" [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE MODIFIED="2012-06-08 19:12:28 +0100" MODIFIED_BY="Jane Cracknell">Data extraction form</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-01 15:13:54 +0100" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="1" ROWS="2">
<TR>
<TD VALIGN="TOP">
<P>
<B>Review title or ID</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intravenous versus inhalation anaesthesia for one-lung ventilation</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="1" ROWS="2">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study ID </B>
<I>(surname of first author and year first full report of study was published e.g. Smith 2001)</I>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
</TABLE>
<P>
 
</P>
<TABLE COLS="1" ROWS="2">
<TR>
<TD VALIGN="TOP">
<P>
<B>Report IDs of other reports of this study </B>
<I>(e.g. duplicate publications, follow-up studies)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
</TABLE>
<P>
 
</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
 
</P>
<SUBSECTION>
<HEADING LEVEL="3">1.     General information</HEADING>
<P>
 
</P>
<TABLE COLS="2" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>Date form completed</B> <I>(dd/mm/yyyy)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Name/ID of person extracting data</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Publication type</B>
</P>
<P>
<I>(e.g. full report, abstract, letter)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Possible conflicts of interest</B>
</P>
<P>
<I>(for study authors)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Notes:</B>      </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
 
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.     Study eligibility</HEADING>
<P>
 
</P>
<TABLE COLS="7" ROWS="9">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Characteristics</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Eligibility criteria</B>
</P>
<P>
<I>(insert eligibility criteria for each characteristic as defined in the Protocol)</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
<P>Yes</P>
</TD>
<TD VALIGN="BOTTOM">
<P>No</P>
</TD>
<TD VALIGN="BOTTOM">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Type of study</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Randomized controlled trial</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Quasi-randomized trial</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Participants</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Types of interventions</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Types of outcome measures</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
<P> </P>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<BR/>
<B>INCLUDE</B> <BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>
<BR/>
<B>EXCLUDE</B> <BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Reason for exclusion</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3.     Population and setting</HEADING>
<P> </P>
<TABLE COLS="3" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description</B>
</P>
<P>
<I>Include comparative information for each group (i.e. intervention and controls) if available</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Population description</B>
</P>
<P>
<I>Adults (&gt; or equal to 18 years old) undergoing myocardial revascularization, regardless of gender, with or without extracorporeal circulation</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Setting</B>
</P>
<P>
<I>(including location and social context)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inclusion criteria<BR/>
<BR/>
<BR/>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exclusion criteria<BR/>
<BR/>
<BR/>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Method/s of recruitment of participants</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4.     Methods</HEADING>
<P> </P>
<TABLE COLS="3" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Descriptions as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aim of study</B>
</P>
<P>
 
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Design </B>
<I>(e.g. parallel, cross-over, cluster)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Unit of allocation</B>
</P>
<P>
<I>The unit of analysis will be each participant recruited into the trials</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Period of study/recruitment</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Follow-up</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5.     Risk of bias assessment</HEADING>
<P> </P>
<TABLE COLS="6" ROWS="12">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Domain</B>
</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Risk of bias</B>
</P>
<P> </P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Support for judgement</B>
</P>
<P> </P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Low risk</P>
</TD>
<TD VALIGN="TOP">
<P>High risk</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Random sequence generation</B>
</P>
<P>
<I>(selection bias)</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Allocation concealment</B>
</P>
<P>
<I>(selection bias)</I>
</P>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>
<I>(performance bias)</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Outcome group: all/     </B>
</P>
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>(if required)</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Outcome group: </B>     </P>
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>
<I>(detection bias)</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Outcome group: all/     </B>
</P>
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>(if required)</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Outcome group: </B>     </P>
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>
<I>(attrition bias)</I>
</P>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Selective outcome reporting?</B>
</P>
<P>
<I>(reporting bias)</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Other bias</B>
</P>
<P>
 
</P>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6.     Participants</HEADING>
<P>
<I>Provide overall data and, if available, comparative data for each intervention or comparison group.</I>
</P>
<P> </P>
<TABLE COLS="3" ROWS="12">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>(pg &amp; ¶/fig/table)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total no. randomized </B>
</P>
<P>
<I>(or total pop. at start of study for NRCTs)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total no. analysed</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Baseline imbalances<BR/>
<BR/>
<BR/>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Withdrawals and exclusions</B>
</P>
<P>
<I>(if not provided below by outcome)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Age</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Sex</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comorbidities</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Other relevant sociodemographics</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Subgroups measured</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Subgroups reported</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7.     Intervention groups</HEADING>
<P>
<I>Copy and paste table for each intervention and comparison group.</I>
</P>
<P> </P>
<P>
<B>Intervention Group 1: Intravenous anaesthesia </B>
</P>
<TABLE COLS="3" ROWS="8">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Group name</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>No. randomized to group</B>
</P>
<P>
<I>(specify whether no. people or clusters)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total no. analysed per group</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Description </B>
<I>(include sufficient detail for replication, e.g. content, dose, components)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Duration of treatment period</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Timing </B>
<I>(e.g. frequency, duration of each episode)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P> </P>
<P> </P>
<P>
<B>Control group: Group 2: Inhalation anaesthesia </B>
</P>
<TABLE COLS="3" ROWS="8">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Group name</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>No. randomly assigned to group</B>
</P>
<P>
<I>(specify no. people or clusters)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total no. analysed per group</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Description </B>
<I>(include sufficient detail for replication, e.g. content, dose, components)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Duration of treatment period</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Timing </B>
<I>(e.g. frequency, duration of each episode)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P> </P>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8.     Outcomes</HEADING>
<P>
 
</P>
<P>
<B>Outcome 1.1</B>&#65293;<B>Death (at one month)</B>
</P>
<TABLE COLS="4" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome name</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points measured</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points reported</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome definition </B>
<I>(with diagnostic criteria if relevant)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Person measuring/reporting</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is outcome/tool validated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Imputation of missing data</B>
<BR/>
<I>(e.g. assumptions made for ITT analysis)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Assumed risk estimate</B>
</P>
<P>(<I>e.g. baseline or population risk noted in Background)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
<B>Outcome 1.2</B>&#65293;<B>Mortality rate (at six months)</B>
</P>
<TABLE COLS="4" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome name</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points measured</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points reported</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome definition </B>
<I>(with diagnostic criteria if relevant)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Person measuring/reporting</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is outcome/tool validated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Imputation of missing data</B>
<BR/>
<I>(e.g. assumptions made for ITT analysis)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Assumed risk estimate</B>
</P>
<P>(<I>e.g. baseline or population risk noted in Background)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P>
<B>Outcome 2</B>&#65293;<B>Abandonment of one-lung technique</B>
</P>
<TABLE COLS="4" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome name</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points measured</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points reported</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome definition </B>
<I>(with diagnostic criteria if relevant)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Person measuring/reporting</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is outcome/tool validated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Imputation of missing data</B>
<BR/>
<I>(e.g. assumptions made for ITT analysis)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Assumed risk estimate</B>
</P>
<P>(<I>e.g. baseline or population risk noted in Background)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P>
<B>Outcome 3</B>&#65293;<B>Length of stay in hospital</B>
</P>
<TABLE COLS="4" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome name</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points measured</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points reported</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome definition </B>
<I>(with diagnostic criteria if relevant)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Person measuring/reporting</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is outcome/tool validated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Imputation of missing data</B>
<BR/>
<I>(e.g. assumptions made for ITT analysis)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Assumed risk estimate</B>
</P>
<P>(<I>e.g. baseline or population risk noted in Background)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P>
<B>Outcome 4</B>&#65293;<B>Economic analysis (by narrative)</B>
</P>
<TABLE COLS="4" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome name</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points measured</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points reported</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome definition </B>
<I>(with diagnostic criteria if relevant)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Person measuring/reporting</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is outcome/tool validated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Imputation of missing data</B>
<BR/>
<I>(e.g. assumptions made for ITT analysis)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Assumed risk estimate</B>
</P>
<P>(<I>e.g. baseline or population risk noted in Background)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P>
<B>Outcome 5</B>&#65293;<B>Oxygen delivery and consumption</B>
</P>
<TABLE COLS="4" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome name</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points measured</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time points reported</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome definition </B>
<I>(with diagnostic criteria if relevant)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Person measuring/reporting</B>
<BR/>
<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is outcome/tool validated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Imputation of missing data</B>
<BR/>
<I>(e.g. assumptions made for ITT analysis)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Assumed risk estimate</B>
</P>
<P>(<I>e.g. baseline or population risk noted in Background)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9.     Applicability</HEADING>
<P> </P>
<TABLE COLS="3" ROWS="4">
<TR>
<TD VALIGN="TOP">
<P>
<B>Have important populations been excluded from the study? </B>
<I>(consider disadvantaged populations and possible differences in the intervention effect)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is the intervention likely to be aimed at disadvantaged groups?</B> <I>(e.g. lower socioeconomic groups)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Does the study directly address the review question?</B>
</P>
<P>
<I>(any issues of partial or indirect applicability)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
           
</P>
<P>Yes     No    Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
 
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">10. Other information</HEADING>
<P> </P>
<TABLE COLS="3" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description as stated in report/paper</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Location in text</B>
</P>
<P>
<I>(pg &amp; ¶/fig/table)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Key conclusions of study authors</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>References to other relevant studies</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
<TD VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Correspondence required for further study information</B> <I>(from whom, what and when)</I>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>     </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Notes:</B>        </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
 
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-06-11 16:03:23 +0100" MODIFIED_BY="Jane Cracknell">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in quantitative synthesis (meta-analysis) 0&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in qualitative synthesis 9&lt;/p&gt;&lt;p&gt;Propofol versus Isoflurane&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 4&lt;/p&gt;&lt;p&gt;Propofol versus Sevoflurane&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 3&lt;/p&gt;&lt;p&gt;Propofol versus Halothane&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1&lt;/p&gt;&lt;p&gt;Ketamine versus Enflurane&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="151">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of full-text articles assessed for eligibility 45&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened 2,101&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database searching 2,099&lt;/p&gt;&lt;p&gt;Pubmed&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 902&lt;/p&gt;&lt;p&gt;Embase&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 852&lt;/p&gt;&lt;p&gt;Central&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 34&lt;/p&gt;&lt;p&gt;Lilacs&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 0&lt;/p&gt;&lt;p&gt;Web of science&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;311&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of additional records identified through other sources 2&lt;/p&gt;&lt;p&gt;Conference proceedings 2&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;# of records excluded 2,055&lt;/p&gt;&lt;p&gt;Irrelevant, review or no-RCT 2,055&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of full-text articles excluded, with reasons 36&lt;/p&gt;&lt;p&gt;Case series&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 12&lt;/p&gt;&lt;p&gt;Controlled clinical trial&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3&lt;/p&gt;&lt;p&gt;Retrospective studies&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2&lt;/p&gt;&lt;p&gt;Interventions not relevant&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 18&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="152"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in the whole review 0&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in the first update 11&lt;/p&gt;&lt;p&gt;Awaiting classification studies 04&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of full-text articles assessed for eligibility 16&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened 1798&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database searching 705&lt;/p&gt;&lt;p&gt;Pubmed&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 32&lt;/p&gt;&lt;p&gt;Embase&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 47&lt;/p&gt;&lt;p&gt;Central&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 346&lt;/p&gt;&lt;p&gt;Lilacs&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 73&lt;/p&gt;&lt;p&gt;Web of science&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;207&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database reran searching 1093&lt;/p&gt;&lt;p&gt;Pubmed 40&lt;/p&gt;&lt;p&gt;Embase 92&lt;/p&gt;&lt;p&gt;Central 361&lt;/p&gt;&lt;p&gt;Lilacs 27&lt;/p&gt;&lt;p&gt;Web of science 573&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of additional records identified through other sources 0&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="191"/>
<OUT TEXT="&lt;p&gt;# of records excluded 1780&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of full-text articles excluded in this update, with reasons 1&lt;/p&gt;&lt;p&gt;Assessed two volatile anaesthetics 1&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>